Monthly Archives: July 2021

Abandonment of Family Planning among Women in Period of Genital Activity in the City of Mahajanga Madagascar

DOI: 10.31038/AWHC.2021442

Introduction

The World Health Organization or WHO defines family planning as the set of measures to promote births, act on the interval between births, prevent unwanted births and give each couple the means of determining the number of children he wants [1].

Poor access to family planning is associated with unintended pregnancies and poorer maternal and newborn outcomes, including abortion-related morbidity and mortality [2]. Unmet need for contraception refers to the percentage of sexually active and fertile women who either no longer want children or are delaying the next child, but are not using contraception. Meeting unmet need helps increase contraceptive use and reduce unintended pregnancies, which improves health outcomes and offers great social and economic benefits to women, their families, and society [3].

According to the WHO, in developing countries that wish to delay having a child or stop having children but do not use any contraception, the number of women is estimated at 225 million [4].

Family planning therefore appears as one of the solutions likely to allow socio-economic development to gain some ground in relation to population growth [5].

Madagascar faces many demographic and health challenges which have negative consequences on economic emancipation. The country has a young population, two-thirds of which are under the age of 25 [6]. The first step in the process of accelerating economic growth is based on declining fertility [7]. Note that the national fertility index was 4.9 in 2018 [8].

According to the 2012-2018 annual report, the modern contraceptive coverage rate has increased considerably, from 27.8% in 2012 to 34.6% in 2018. On the other hand, the unmet need for contraceptive methods has decreased by 28%. in 2012 to 24.9% in 2018 [9].

Increasing access to family planning and meeting unmet need for contraception are key goals for improving reproductive health. Madagascar is committed to the Global Family Planning 2020 partnership to improve access to family planning [6].

Thus, stopping contraceptives has significant repercussions, not only for family planning and maternal and child health, but also for population growth and the overall economic development of countries. Most women who stop using contraceptives do so at the start of their contraceptive use and without consulting a health care professional [10].

A study on family planning dropouts seemed necessary to us in Mahajanga, in order to identify the causes of women abandoning contraception.

Methodology

We carried out this study in the city of Mahajanga, among women in genital activity. This is a 3-month observational, descriptive and cross-sectional study, running from August 1 to October 31, 2019.

We included in this study all women aged 15 to 49 who had agreed to participate in the survey and had temporarily or permanently abandoned the contraceptive method.

The parameters evaluated were the variables related to the socio-demographic profiles of the women, to the data concerning the knowledge of these women in matters of family planning and the causes of discontinuation or abandonment.

Results and Discussion

Among these women who had abandoned modern contraceptive methods, 33.46% had used pills, 31.91% injectables and 27.63% condoms. In the other studies as well, users of pills and injectable contraceptives were the most frequent users of family planning, but in different proportions [11,12].

It was a temporary abandonment in 95.33% of cases, final in 4.67%. Several reasons were mentioned by the women, but the most important were the desire for a child, the opposition of the husband or partner, side effects, rumors and contraceptive failure. Thus, the desire for a child was the first motive pushing women to abandon modern contraception, found in 31.5% of cases.

This result was comparable to those of other studies which found that stopping the use of contraceptive methods was mainly due to a desire to have a child [13-15].

This would explain the relatively small number of children in our study, which witnessed not reaching the desired number of children. Partner opposition was the second reason for stopping the contraceptive method, found in 27.20% of cases, as reported in other studies [16,17].

The problem of family planning is a couple’s affair and the role of the partner must be preponderant before and after the choice of the contraceptive method. Yet, according to some authors, the majority of men believe that they have the absolute right, the power to decide on the use of modern contraception by their wives [16,17].

The problem of side effects was the third reason for giving up contraception, with 10.5% of cases. These side effects are multiple and depend on the contraceptive method used. Thus, each user must be informed at the time of the choice [18,19].

Negative rumors, mentioned by 10.1% of women, represent a phenomenon that compromises the development of modern contraceptive use. According to these rumors, modern contraceptives are the cause of serious disease such as cervical cancer or breast cancer, and are the cause of secondary infertility.

Thus, these rumors cause concern among users and may lead them to quit permanently, bringing back to the question of the sufficiency of information on family planning [20,21].

Among the women surveyed who temporarily gave up family planning, the majority resumed contraception using the same contraceptive method as before. Thus, the female family planning users in this study were almost faithful to the latest methods they used, despite the various reasons for quitting.

In addition, they were easy to convince about the use of family planning in the future, while the remaining 12%, those who encountered difficulties, said they did not intend to use it in the future.

Conclusion

The study on the reasons for abandoning the contraceptive method of women of childbearing age carried out in the city of Mahajanga has provided interesting information.

The results of this study showed that the majority of women surveyed were already aware of the existence of different contraceptive methods, and they were in favor of the use of modern contraception.

Among contraceptive methods, pills rank first, followed by injectable methods and condoms. The majority of these women are under 30, married or single, self-employed, with more than one living child, with at least secondary education. In almost 90% of cases, they gave up contraception temporarily for different reasons. For example, the desire for a child, lack of information, fear of opposition from a family member, and side effects were cited as reasons for giving up or not using contraceptive methods. Therefore, any effort to increase contraceptive prevalence should target these factors to optimize achievement of this goal.

Keywords

Abandonment, Family planning, Woman, Mahajanga

References

  1. Gentilini M (1988) Tropical Medicine. Paris: Flammarion.
  2. Ahmed S, Li Q,Liu L,Tsui AO (2012) Maternal Deaths Alerted by Contraceptive Use: An Analysis of 172 Countries. Lancet 380: 111-125. [crossref]
  3. Andrzej K (2018) Overcoming the Challenges of Family Planning in Africa: Towards Meeting Unmet Needs and Increasing Service Delivery; African Journal of Reproduction Health 22: 14-15. [crossref]
  4. Family planning. WHO 2016 May [Accessed 07/07/2019]. Available at the URL http://www.who.int/topics/family_planning/fr/
  5. Alkema L, Chou D,Hogan D, Zhang S,Moller AB, et al. (2015) Global, regional, and national levels and trends in maternal mortality between 1990 and 2015, with scenario-based projections to 2030: a systematic analysis by the UN Maternal Mortality Estimation Inter-Agency Group. Lancet 387 : 462-474. [crossref]
  6. Ministry of Public Health. National budgeted action plan for family planning in Madagascar 2016-2020: MSP.2016; 9-21.
  7. UNFPA Madagascar. National Conference on Family Planning: Demographic Dividend. September 14, 2016
  8. Multiple Indicator Cluster Surveys. Fertility and Family Planning: INSTAT .MICS.Madagascar.2018
  9. Summary of Main Indicators: FP2020 Annual Report 2018-2019. Madagascar. 2019
  10. Castle S and Askez I (2015) Stopping Contraceptives: Reasons, Challenges, Solution. Preliminary Report. Population Council 47.
  11. Summary of Key Indicators: FP2020 Annual Report 2018-2019. Ethiopia. 2019.
  12. Summary of Key Indicators: FP2020 Annual Report 2018-2019. Rwanda. 2019.
  13. Andriamialisoa (2007) Epidemiological profile of those lost to follow-up family planning at the CSB2 of Moramanga: Thesis in Med Tana 47.
  14. Mahamadou S (2019) Use of Family Planning services in the health area of the rural commune of Farako of the health district of Ségou from January 1 to December 31, 2018: Thesis in Med. BAMAKO. 45.
  15. Ravonisoa (2006) Family Planning: The reasons for the low use in Analavory, Manakara in 2006: Thesis in Med Tana. N ° 7530. 44.
  16. Mahougnon AT (2019) Choice and effectiveness of contraceptive methods: a reduction in unmet need for family planning. International Review of Marketing and Strategic Management 1: 23-42.
  17. Vouking MZ, Evina CD, Tadenfok CN (2014) Male involvement in family planning decision making in sub-Saharan Africa-what the evidence suggests. The Pan African Medical Journal 7: 19-33. [crossref]
  18. PSI Madagascar (2003) Study on the knowledge, attitudes and practices of young people aged 15 to 24 in Toamasina in terms of family planning. PSI / Mad. 2003: 6-9.
  19. Vololoniaina N (2007) Prevalence of side effects of modern contraceptives to CSB2 of Amparafaravola. Antananarivo: Medicine thesis n ° 5812: 27-30.
  20. Razafimiarantsoa TT (2004) Exposure to the risk of pregnancy. EDS 97-107.
  21. PSI Madagascar (2006) Family planning training. Antananarivo: Institute of Educational Technology and Management 14-15.

Case Report of Neuron-Binding IgGs in ALS Patient Serum in Argentina

DOI: 10.31038/JNNC.2021423

Abstract

Amyotrophic Lateral Sclerosis (ALS) is a degenerative disorder characterized by ongoing loss of motoneurons. The etiology of the sporadic ALS form it is thought to be related to immune-mediated motoneuron degeneration and death. The present study was designed to describe the effect of serum factors derived from sporadic ALS patients on mouse spinal cord preparations in vitro. Sera from patients with sporadic ALS were collected and used for immunofluorescence analysis to investigate their effects on neuronal survival and microgliosis. Our experiments demonstrated that 5 h application of serum factors (derived from three ALS patients) labeled with human IgG secondary antibody were localized to ventral spinal neurons identified with the NeuN marker. Moreover, a significant reduction in the number of ventral NeuN positive cells was observed with serum from a patient who suffered from upper motor neuron signs as criteria for ALS diagnosis (20% less compared to sham, spinal cord preparations without serum). No change in microglia number was found after exposure to ALS sera, although in two cases a significant decrease in microglial branch length was observed (28-32%). Microglia morphology showed increased number of end points and branches with serum from the patient with upper motor neuron symptoms. These observations were absent after control sera. Our data indicate that spinal cord cultures can be a useful model to further characterize the pathological processes of sporadic ALS and the immune mechanism as previously suggested in vivo. Future studies are needed to unveil the molecular mechanisms underlying this preferential targeting of neurons and microglia by ALS serum.

Keywords

Amyotrophic lateral sclerosis, Autoimmunity, Microglial activation, Neuron labeling

Non-standard Abbreviations

ALS, Amyotrophic Lateral Sclerosis; HC1 (2), serum form healthy control 1 (2); Iba-1, ionized calcium-binding adapter molecule; IgG, immunoglobulin; MNs, motor neurons; NeuN, neuronal-specific nuclear protein; P1 (2 and 3) serum from ALS sporadic patient 1 (2 and 3); PBS, phosphate-buffered saline.

Highlights

  • Immune mechanisms contribute to ALS pathology at spinal cord.
  • Unlike controls, ALS serum factors bound spinal ventral neurons.
  • Microglia morphological changes were induced by ALS serum factors.
  • In vitro spinal preparations can be a useful platform to study immunopathology of ALS.

Introduction

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that affects motoneurons with fatal outcome usually within 2-5 years [1]. Although the aetiology and pathogenesis of ALS are unknown increasing evidence supports immune-mediated mechanisms, although this remains controversial [2]. Our previous studies have demonstrated that motor nerve terminals are a target for autoimmune response, induced by immunoglobulin’s (IgGs) from sporadic ALS patients, resulting in neuromuscular dysfunction in vivo [3]. Indeed, IgGs obtained from patients with ALS reduce Ca2+ transients and glutamate receptor desensitization so that excitotoxic damage is facilitated in a culture brain neuron model [4]. Furthermore, we have shown that subcutaneous injection of ALS-IgG into the levator auris muscle were immunoreactive to spinal motoneurons, preferentially accumulate in the soma by binding to unknown specific cytoplasmic targets [5]. The question then arises about the role of ALS serum factors on spinal cord neurons and the inflammatory process that would be associated with the disease onset and development. In vitro spinal cord preparations have been exploited as a model to investigate early pathophysiological mechanisms of spinal cord damage and developmental changes in cellular profiles [6]. The aim of the present study was to investigate, using neonatal mouse spinal cord preparations in vitro, the effect of serum from sporadic ALS patients. Thus, sera from patients with sporadic ALS diagnosis in accordance with the El Escorial criteria [7] and from healthy volunteer subjects were tested on neuronal numbers and microglia morphology.

Materials and Methods

Preparation of Mouse Spinal Cord Cultures and ALS Serum Incubation

Thoracolumbar spinal cord preparations were isolated from neonatal C57BL/6 mice (1-3 day old) in accordance with standard procedures [8]. Briefly, spinal cords were dissected with Krebs’ solution of the following composition (in mM): NaCl, 113; KCl, 4.5; MgCl2.7H2O, 1; CaCl2, 2; NaH2PO4, 1; NaHCO3, 25; glucose, 11; gassed with 95% O2 5% CO2; pH 7.4 at room temperature. After dissection spinal slice cultures were incubated with sera from sporadic ALS patients (listed as P1, P2 and P3) in standard Krebs’ solution (1:1000) for 5 h at room temperature. Patients were diagnosed with sporadic ALS according to clinical criteria that included progressive paralysis with mixed upper and lower motor neuron signs (1 woman and 2 men) [7]. Healthy control serum was collected from two subjects (HC1 and HC2) with no evidence of neurological disease. The serum samples were obtained with prior consent from patients attending the FLENI clinic. Mouse spinal cord controls, without any serum treatment (sham), were processed in parallel to test preparations in each experiment. After incubation, all spinal cord tissues were immediately fixed in phosphate-buffered saline (PBS) containing 4% paraformaldehyde (24 h at 4°C) followed by 30% sucrose PBS for cryoprotection (24 h at 4°C) for immunostaining.

Slice Immunostaining and Cell Analysis

Full details of this procedure have previously been published [6]. In brief, spinal cord slices (30-µm thick) were collected sequentially on histology slides. Slices were blocked with fetal calf serum (3%), bovine serum albumin (3%) and Triton X-100 (0.3%) in PBS for 1 h at room temperature, followed by overnight incubation at 4°C in blocking solution containing the following antibodies: NeuN (neuronal-specific nuclear protein, 1:300, Millipore, Billerica, MA, USA) for neurons and Iba-1 (ionized calcium-binding adapter molecule 1, 1:500, Wako, Osaka, Japan) for microglia. Primary antibodies were visualized using the corresponding secondary fluorescent antibody (at 1:500 dilution; Invitrogen, Carlsbad, CA, USA). The serum factors from ALS patients were recognized by an anti-human IgG secondary antibody (at 1:500 dilution; Invitrogen). Since the staining was diffuse, data quantification was performed in terms of immunofluorescence intensity (expressed in arbitrary units, AU) obtained with a line scan of each image to verify the nuclear distribution of IgG according to NeuN soma size measured with ImageJ software (NIH, https://imagej.nih.gov/ij/index.html)http://imagej.nih.gov. For each slice culture, the number of NeuN positive cells was obtained by counting stacks of 10 images (40x magnification) with FV300 confocal microscope (Olympus Optical, Tokyo, Japan), and quantified using ImageJ software. NeuN positive cells were counted in two ROIs (namely, dorsal, and ventral) in an area= 90488, 5 µm². In view of the very large number of histological sections provided by each spinal cord the final numbers of counted cells were expressed as fold average respect to sham, obtained from an equivalent number of sections by experiment.

The morphology of Iba1-positive cells was analysed by the ‘skeleton’ method [9]. Thus, the signal from Iba1-positive processes was enhanced to optimize their detection followed by noise de-speckling to eliminate background fluorescence. The resulting images were converted to binary data and then ‘skeletonized’ by using ImageJ software. The Analyze Skeleton plug-in (http://imagejdocu.tudor.lu) was then applied to Iba-1 images to collect mean raw data on the number of branches, end points and process lengths.

Data Analysis

Data were expressed as means ± S.E.M; n = number of slices from 5 different independent experiments. Statistical analysis was carried out with SigmaStat (SigmaStat 3.1, Systat Software, Chicago, IL, USA). For multiple comparisons, the analysis of variance (ANOVA) test for parametric data followed by the Tukey-Kramer post hoc test was used. Nonparametric values were analyzed with the Kruskal-Wallis test. The accepted level of significance was always p < 0.05.

Results

Clinical diagnosis of sporadic ALS was achieved by careful patient history collection, plus physical and neurological examination according to El Escorial criteria [7] and evidence of signs of lower or upper motor neuron degeneration. Hence, two patients were classified with lower motor neuron (P1 and P3) and one patient with upper motor neuron degeneration (P2). In vitro slice preparations of the neonatal spinal cord were treated with healthy control serum (HC), patient serum (P) or without serum (sham condition) for 5 h at room temperature. Figure 1A shows examples of immunohistochemistry analysis to identify neurons (NeuN, in green. Figure 1A top row), human immunoglobulins (IgG, light blue, Figure 1A lower row) and microglia (Iba-1, in red, Figure 1E).

Ventral Neuronal Labeling with ALS Serum Factors

Figure 1A and 1B shows that serum factors from all ALS patients labeled with the anti-IgG human secondary antibody were localized to NeuN positive neuronal cells. The quantification of mean immunofluorescence intensity for IgG signal was analyzed for different neuronal soma size. Figure 1B demonstrates higher mean fluorescence intensity (arbitrary units, AU) for P1, P2 and P3 in comparison to sham and HC1 and HC2 in the ventral spinal region. On the contrary a unique soma size IgG signal labeling was observed at dorsal region, data not shown. As exemplified in Figure 1C and 1D, the number of dorsal NeuN positive cells was consistent throughout samples. Conversely, a significant reduction in neuron number at the ventral spinal region was observed following serum from patient 2 (**p ≤ 0.01 vs. sham, n=3-10, Kruskal-Wallis one-way analysis of variance on ranks test).

Microglial Phenotypes Observed after ALS Serum Factors

The immunohistochemical staining for Iba-1 microglia marker was evaluated in ventral spinal regions after ALS serum incubation, as shown in Figure 1E. There was no significant change in the number of Iba1-positive cells. However, a morphological change in microglia was observed for P2 with significant increase in the number of microglial branches and endpoints (Figure 1F and 1G, ***p ≤ 0.001 vs. sham, &&& p ≤ 0.001 vs. HC, n=4-10, Mann-Whitney test). The vast majority microglia of P1 and P2 also showed a significant reduction in branch length (Figure 1H, *p ≤ 0.05 vs. sham, n=4-10, Mann-Whitney test).

fig 1

Figure 1: Neurons and microglia immunolabeling after incubation with serum factors derived from ALS patients in vitro spinal cord preparations. (A) Examples of neuron staining (NeuN, green) and serum factors that were identified by anti-human IgG labeling (light blue) in the ventral region of the spinal cord for sham, healthy serum (HC), serum from patients with sporadic ALS (P1, P2 and P3). (B) Plots showing IgG mean fluorescence intensity quantification (arbitrary units, AU) that colocalized with NeuN staining by measuring different neuronal soma size (µm). Results are expressed as raw data for in vitro spinal cord preparations for sham, HC (HC1 grey dots and HC2 black dots, respectively) and for P1, P2 and P3 at ventral region. (C-D) Histograms showing the fold of NeuN positive cells in dorsal and ventral area related to sham condition, or after 5h of incubation. No differences in the number of neurons were found in dorsal spinal cord region. (D) There was a significant decrease in the number of neurons following serum from P2 at the ventral region, n=3-10, **p<0.05 vs. sham. (E-H) Iba-1 morphological changes after ALS serum incubation. (E) Examples of microglia staining (Iba-1 in red) in mouse isolated spinal cord. Histograms showing the raw data for number of branches (F), end points voxels (G), and average branch length (H, in µm) for Iba-1 in ventral region of spinal cord cultures. In the ventral region there was a significant change in microglia morphology for P2, with a significant reduction in the average branch length of microglia also for P1 (G), n=4-10, *p<0.05 vs. sham, ***p<0.001 vs. sham, &&&p<0.001 vs. HC.

Discussion

Most studies describe the role ALS effects on lower MNs in the spinal cord and brain stem, and upper MNs in the motor cortex [10]. While ALS is a multifactorial disease with diverse aetiology, the main cause of its onset in the sporadic form is still unknown, although it is suspected that the activity of the immune system impacts its course and development [1]. Several studies show that, in this immune response, the IgG of the patients play a fundamental role as triggers of the disease [2]. The present report shows that serum factors derived from three patients labelled with human IgG secondary antibody were localized to ventral spinal neurons. Interestingly, the sera of all three ALS sporadic patients induced large soma size labeling of ventral neurons and microgliosis in in vitro spinal cord preparations.

Ventral Neurons were Labeled by ALS Serum Factors

Our previous studies demonstrated that ALS-IgG injected into the mouse levator auris muscle significantly immune react with nerve terminals and, by retrograde axonal transport, are actively accumulated in the MNs soma [5]. Here we have shown that most large soma size ventral spinal neurons were immunoreactive to serum factors derived from patients with the sporadic ALS form. Indeed, we could not observe a clear preference of ALS serum for a certain neuronal type. However, in this study it is expected that ALS IgG have been in contact with every single neuron while, in our previous study, ALS IgG reached the MNs via the motor axons. We have shown that the cellular composition varies between dorsal and ventral spinal regions, the latter being characterized by the presence of differential soma size interneurons as well as MNs [6]. Indeed, our pervious data have also demonstrated that ALS does not affect all neurons, but mainly certain types of MNs [5]. Our early studies have shown that the delayed neuroprotection by riluzole after kainate treatment, to mimic excitotoxicity as one major factor MN degeneration in ALS, was observed in the dorsal and central regions, but not in the ventral one [11]. The different neuronal vulnerability in the spinal cord [8,12], probably related to the neuron-selective ability by different protocols to induce neuroprotection, might highlight preference of ALS serum binding to large ventral neurons. Our results also demonstrate that binding of serum is not a trigger for neurodegeneration, at least within the short time of experimental serum application. A likely explanation, in addition to selective large cell binding, is that MNs have a delicate metabolic state and are perhaps more susceptible to any intracellular signalling process that can be initiated by the pathological ALS serum in vitro [13]. Further studies are needed to clarify the molecules responsible for this phenomenon, as well as the mechanism of IgG to differential cell labeling on sporadic ALS onset.

Microglia Morphological Changes Induced by ALS Serum Factors

To advance our understanding of ALS pathogenesis and the role of inflammatory processes, an immunofluorescence study with Iba-1, a microglial marker, was performed. Inflammation is mostly related to deterioration in neuronal function and involves a change of microglia number or morphological phenotypic changes. Our results demonstrated that the number of microglia in both dorsal and ventral areas did not vary after incubation with serum from patients or voluntary healthy controls. A simple explanation for this result is that neuroinflammation (if any) would not be initially characterized by microglia proliferation [14]. However, another important characteristic of neuroinflammation is the different states of microglia activation. When the inflammatory process occurs, microglia can pass from rest to different phenotypic active states [14]. In the present study serum factors derived from a patient with upper motoneuron degeneration induced significant microglia morphological change. Further studies will be needed to determine if this inflammatory change is a cause or consequence of neuronal degeneration.

Final Considerations and Conclusion

The present findings provide further evidence in favour of immunological mechanisms contributing to ALS pathology and disease progression in the spinal cord. In vitro spinal cord preparation is a useful model to explore the basic molecular mechanisms and cellular consequences of ALS.

Acknowledgments

We thank Maria Eugenia Martin for the assistance with the spinal preparations. We thank Dr. Andrea Nistri and Dr. Carly Mc Carthy for invaluable comments and critical reading of the manuscript. This study was supported by Universidad Austral, FLENI, CONICET and Grant 01/Q666 (20020130100666BA; Universidad de Buenos Aires Ciencia y Tecnología [UBACYT]) from University of Buenos Aires (to O.D.U.).

Declaration of Competing Interest

None declared.

References

  1. Beers DR, Appel SH (2019) Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol 18:211-220. [crossref]
  2. Pagani MR, Gonzalez LE, Uchitel OD (2011) Autoimmunity in amyotrophic lateral sclerosis: past and present. Neurol Res Int 2011: 497080. [crossref]
  3. Gonzalez LE, Kotler ML, Vattino LG, Conti E, Reisin RC, et al. (2011) Amyotrophic lateral sclerosis-immunoglobulins selectively interact with neuromuscular junctions expressing P/Q-type calcium channels. J Neurochem 119: 826-838. [crossref]
  4. Andjus PR, Khiroug L, Nistri A, Cherubini E (1996) ALS IgGs suppress [Ca2+]i rise through P/Q-type calcium channels in central neurones in culture. Neuroreport 7: 1914-1916. [crossref]
  5. Fratantoni SA, Dubrovsky AL, Uchitel OD (1996) Uptake of immunoglobulin G from amyotrophic lateral sclerosis patients by motor nerve terminals in mice. J Neurol Sci 137:97-102. [crossref]
  6. Cifra A, Mazzone GL, Nani F, Nistri A, Mladinic M (2012) Postnatal developmental profile of neurons and glia in motor nuclei of the brainstem and spinal cord, and its comparison with organotypic slice cultures. Dev Neurobiol 72:1140-1160. [crossref]
  7. Brooks BR (1994) El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop contributors. J Neurol Sci 124: 96-107. [crossref]
  8. Mazzone GL, Margaryan G, Kuzhandaivel A, Nasrabady SE, Mladinic M, et al (2010) Kainate-induced delayed onset of excitotoxicity with functional loss unrelated to the extent of neuronal damage in the in vitro spinal cord. Neuroscience 168: 451-462. [crossref]
  9. Mazzone GL, Mladinic M, Nistri A (2013) Excitotoxic cell death induces delayed proliferation of endogenous neuroprogenitor cells in organotypic slice cultures of the rat spinal cord. Cell Death Dis 4: e902. https://doi.org/10.1038/cddis.2013.431
  10. Shaw PJ (1999) Motor neurone disease. BMJ 318:1118-1121. https://doi.org/10.1136/bmj.318.7191.1118
  11. Mazzone GL, Nistri A (2011) Delayed neuroprotection by riluzole against excitotoxic damage evoked by kainate on rat organotypic spinal cord cultures. Neuroscience 190: 318-327. [crossref]
  12. Taccola G, Margaryan G, Mladinic M, Nistri A (2008) Kainate and metabolic perturbation mimicking spinal injury differentially contribute to early damage of locomotor networks in the in vitro neonatal rat spinal cord. Neuroscience 155: 538-555. [crossref]
  13. Comoletti D, Muzio V, Capobianco A, Ravizza T, Mennini T (2001) Nitric oxide produced by non-motoneuron cells enhances rat embryonic motoneuron sensitivity to excitotoxins: comparison in mixed neuron/glia or purified cultures. J Neurol Sci 192: 61-69. [crossref]
  14. Graeber MB (2010) Changing face of microglia. Science 330: 783-788.

Why Public Health Interventions Need a Multidisciplinary Approach to Understand and Address Behaviours Effectively?

DOI: 10.31038/PEP.2021241

Abstract

Although we have made significant efforts in controlling disease with strong improvements in, for instance, people’s life expectancy, it is obvious that the 21st Century is full of health challenges such as unhealthy behaviors which are fueled by the way societies are organized so that there must be another focus on how we consider health and health issues in order to be more effective in addressing them. The objective of this reflection is to call upon the importance of a genuine understanding of health and ways of its improvement through interventions that address behaviors effectively while we are facing challenges that are different from the ones in the past centuries.

Keywords

Ecological approach of health; Transdisciplinary approach and effective behavior change interventions

Introduction

When considering health and health issues throughout centuries behind, it is obvious that improvements have been made with great achievements like the one on people’s life expectancy. After strong efforts to control disease in the past, the 21st Century is facing some different health challenges and unhealthy behaviors in a rapid changing world. The way societies are organized, dealing with development processes that are not getting all citizens onboard, the consequences of the climate change, the rapid demographic changes, globalization, and technological advances, among others, are impacting strongly health of populations [1]. If from the beginning, researchers could be skeptics with the World Health Organization (WHO) definition of health, nowadays there is great interest to consider that definition which leads to a comprehensive view of health so that by positioning people on a good level of the social ladder they will improve health and increase resilience [2].

The objective of this reflection is to call upon the importance of a genuine understanding of health and ways of its improvement through interventions that address behaviors effectively while we are facing challenges that are different from the ones in the past centuries.

Ecological Model of Health

According to WHO, “health is a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity” [3]. This means that to be ‘healthy’, one should be well physically, mentally and socially. Health has been seen on different ways mainly with three major models: the biomedical model that views health as the absence of diseases or disorders; the behavioral model that views health as the product of making healthy lifestyle choices; and the socio-environmental model that views health as the product of social, economic and environmental determinants that provide incentives and barriers to the health of individuals and communities. This third model which is the more holistic way of viewing health is known also as biopsychosocial model or ecological model [4]. It emphasizes the linkages and relationships among multiple factors (determinants) affecting health. These determinants include biology, the social and physical environment, education, employment, and behavior. Dahlgren and Whitehead [5] drafted an example of the ecological model as shown in Figure 1 with one omitted factor, the general/local political context.

fig 1

Figure 1: Example of the ecological model of health according to Dahlgren & Whitehead [5].

Gebbie et al. [1] explained that while an ecological model addresses the interactions and linkages among determinants of health, there are related concepts to it. The first is an ecological view of health which is a perspective that involves knowledge of the ecological model of determinants of health and an attempt to understand a specific problem or situation in terms of that model. The second is an ecological approach to health which is the one that develops multiple strategies to impact determinants of health relevant to the desired health outcomes. It is then to say that addressing public health challenges requires an ecological approach with its implications among which the transdisciplinary approach and health professionals who are fully prepared to work with others to improve health.

Why should one, in dealing with health issues, considering not the ecological approach and its emphasis on the social determinants of health?

Social Determinants of Health and the Necessity for Transdisciplinary Interventions

The health challenges we are facing in this 21st Century which are, among others, the high level of consciousness of population’s health with lot of investments but without consistent results could be compared to the ones that led Canadian Government in the 1970s to the Lalonde Report [6] with the important notion of determinants of health.

Determinants of health include: broad social, economic, cultural, and environmental conditions; living and working conditions; social, family, and community networks; individual behavior; individual traits such as age, sex, race, and biological factors, and the biology of disease [1]. According to Blake [7], health can be seen like an iceberg with multiple underpinning determinants that shape it, such as: i) Values including culture, biology and genetic endowment, employment and working conditions, income and social status; ii) Assumptions that comprise personal health practices and coping skills, social environments, social support networks; iii) Beliefs that encompass gender, healthy child development, physical environment, education; and iv) Health services.

A part from individual traits and the biological factors, it is obvious that health is influenced by multiple factors that are the results of how societies are organized, the Social Determinants of Health (SDHs). SDHs are the conditions in which people are (conceived), born, grow, live, work and age including mechanism in place to address diseases [8]. By defining SDHs that way, it is obvious that they are under the responsibility of multiple sectors outside of the health system and are shaped by the distribution of money, power and resources at global, national and local levels [8]. This helps understand that health results are not the responsibility of the health system alone and even, other sectors are more responsible than the health system for the health outcomes [9]. These health results (or health status) which is different across the population and between specific populations groups are mostly the responsibility of the social determinants of health through their distribution. These differences in health status due to how a society is organized to assure a fair distribution of SDHs are avoidable and known as health inequities. By questioning these differences, Evans and colleagues [10] showed the importance of SDHs in maintaining people healthy. Improving health status is then a task for multiple sectors which must work together to achieve better health.

As the WHO Commission on Social Determinants of Health (CSDH) [11] put it in its framework (Figure 2), a patient is a “messenger” telling the practitioner about its living conditions, because illness is a “feedback” on a given individual’s social position. And social position is created by social, economic and political mechanisms, whereby populations are stratified according to income, education, occupation, gender, race/ethnicity and other factors. Socioeconomic positions in turn shape specific determinants of health status reflective of people’s place within social hierarchies. Based on their respective social status, individuals experience differences in exposure and vulnerability to health-compromising conditions and behaviors. In other words, diseases and behaviors are a deeply social process. Their distribution lays bare society’s structures of wealth and power, and the responses they elicit illuminate strongly held values [12]. According to Marmot [2], health and behavior follow a social gradient. A social gradient occurs when the frequency (e.g., of a health problem) increases steadily from the most advantaged to the least advantaged categories [2,13]. One could understand what the CSDH report was saying: “Why treat people and send them back to the conditions that made them sick?” [8] There is absolutely a necessity to change the social position for sick people in order to be treating them adequately. To do so, it must be through a transdisciplinary approach because health system cannot afford to do that alone. That’s why it is an unfinished work all the time people are treated and send back to the same conditions that made them sick.

fig 2

Figure 2: CSDH conceptual framework of social determinants of health inequities [11].

What is then the implication of the ecological approach in addressing health issues and unhealthy behaviors?

Implications of the Ecological Approach in Dealing with Health Issues and Unhealthy Behaviors

With this ecological health perspective, health system has a huge responsibility which covers two main domains that are i) first and most important, the coordination of all other sectors through what WHO called “make every sector a health sector” [8], which means that it has to assume and act on the fact that health is all sectors’ endeavor so that multidisciplinary approaches, when defining barriers and drivers and designing behavioral interventions, should be the corner stone. By so doing, SDHs are addressed, reducing social inequities, improving the living conditions of the populations and leading to healthy behaviors. ii) Second, disease management that has to be in the perspective of the ecological approach as shown in Table 1 according to Swannack and Appleby [14], considering necessarily the underpinning conditions that must be addressed in collaboration with other sectors.

Table 1: Disease management with the ecological model compared to the biomedical model.

Areas of disease management

Biomedical Model

Ecological Model

Considering factors Only takes account of biological factors Takes account of biological, psychological and social factors
Views on what causes illness All physical factors – pathogens, injury, physiological change Multiple factors – physical, social and psychological
Patient responsibility No responsibility on the patient, because all factors are out of the patient’s control There is patient responsibility, because lifestyle has an influence
Treatment style Bodily interventions only Whole person themes, mind and body
Responsibility for treatments Doctor only Doctor and patient combined
Role of psychology No relationship with physical illness Causal influence and consequence of physical illness

Source: Adapted from Swannack & Appleby [14].

As Gebbie and colleagues put it [1], health professionals must look beyond the biological risk factors that affect health and seek to also understand the impact on health of environmental, social, and behavioral factors. They must be aware of how these multiple factors interact in order to evaluate the effectiveness of their interventions. It is their responsibility to understand the theoretical underpinnings of the ecological model in order to develop research that further explicates the pathways and interrelationships of the multiple determinants of health. It is through this understanding that health professionals will be able to more effectively address these 21st century challenges we are facing, including globalization, scientific and medical technologies, and demographic transformations.

Frieden through his Health Impact Pyramid (Figure 3) [15] explained that interventions focusing on lower levels of the pyramid tend to be more effective because they reach broader segments of society and require less individual effort. The base of the pyramid is indicating interventions that have the greatest potential impact and represent efforts to address SDHs. The multisectoral aspect of the pyramid reinforces the maximum possible sustained public health benefit when implementing interventions at each of the levels. One of the levels of that pyramid is clear for what specifically is related to behavior change in stipulating that context must be changed to make individual’s default decisions healthy. Behavior is not only individual’s responsibility (Figure 4) [16-19].

fig 3

Figure 3: The Health Impact Pyramid [15].

fig 4

Figure 4: Complementary approaches to prevention (adapted from Puska 2001) [19].

Taket [20] in a paper entitled “Making partners-intersectoral action for health” clarified what the environment is all about, physical and socioeconomic and in link with the health gradient: poverty, poor housing, unemployment, inadequate food and nutrition, lack of education, environmental health hazards. It is then clear that the weapon we do have to succeed understanding and addressing effectively behaviors is the multisectoral approach in which the health sector has to play an important role of coordinating other sectors through what WHO calls “Action across sectors” [16].

Conclusion

Health cannot be viewed as a simple phenomenon; it is a complex one and then needs that multiple sectors gathered together to solve issues related to it because of that complexity. Working for healthy choices and effective behavior change interventions requires then a multidisciplinary approach that implies the whole-of-society approach with a leading role at local government level and communities equipped with health literacy.

References

  1. Gebbie K, Rosenstock L, Hernandez LM (2003) Who will keep the public healthy? Educating public health professionals for the 21st Committee on Educating Public Health Professionals for the 21st Century. Board on Health Promotion and Disease Prevention, The National Academies Press, Washington D.C., USA. [Crossref]
  2. Marmot M (2004) Status syndrome: How your place on the social gradient directly affects your health. Bloomsbury, London, UK.
  3. World Health Organization (WHO). Preamble to the Constitution of WHO as adopted by the International Health Conference, New York, 19 June – 22 July 1946; signed on 22 July 1946 by the representatives of 61 States (Official Records of WHO, no. 2, p. 100) and entered into force on 7 April 1948.
  4. Houéto D, Laverack G (2014) Promotion de la santé et autonomisation dans le contexte africain, Rossendale Books Editions, Raleigh, USA.
  5. Dahlgren G, Whitehead M (1991) Policies and strategies to promote social equity in health. Stockholm: Institute for the Futures Studies.
  6. Lalonde M (1974) A New Perspective on the Health of Canadians. Ottawa, ON: Ministry of Supply and Services.
  7. Blake (2013) Likely healthy: Public health aims to increase the likelihood of good health at the population level.
  8. World Health Organization (WHO) (2008) Closing the gap in a generation: Health equity through action on the social determinants of health. Final Report of the WHO Commission on Social Determinants of Health. Geneva, Switzerland.
  9. Kottke ET, Pronk PN (2009) Taking On the Social Determinants of Health: A Framework for Action.
  10. Evans GR, Morris L, Theodore R (1994) Why are some people healthy and others not? The determinants of health of populations. New York (USA): Aldine de Gruyter, Social institutions and social change series.
  11. Solar O, Irwin A (2010) A conceptual framework for action on the social determinants of health. Social Determinants of Health Discussion Paper 2 (Policy and Practice). World Health Organization, Geneva, Switzerland.
  12. Jones SD, Podolsky HS, Greene AJ (2012) The Burden of Disease and the Changing Task of Medicine. The New England Journal of Medicine 366: 2333-2338. [Crossref]
  13. Leclerc A, Kaminski M, Lang T (2008) Inégaux face à la santé : du constat à l’action. Institut National de la Santé et de la Recherche Médicale, Ed La Découverte.
  14. Swannack M, Appleby B. Models of Health. 2020. Available from: https://simplemed.co.uk/subjects/population-and-social-science/models-of-health [accessed on 10 December 2020].
  15. Frieden RT (2010) A Framework for Public Health Action: The Health Impact Pyramid. American Journal of Public Health 100: 590-595. [Crossref]
  16. World Health Organization (WHO). Ninth Global Conference on Health Promotion: “Health in the Sustainable Development Goals” Shanghai, China, 21 to 24 November 2016.
  17. World Health Organization (WHO). Shanghai Consensus on Healthy Cities 2016. Healthy Cities Mayors Forum. Ninth Global Conference on Health Promotion, Shanghai, China, 21 November 2016.
  18. World Health Organization (WHO). Jakarta Declaration on Leading Health Promotion into the 21st The Fourth International Conference on Health Promotion: New Players for a New Era – Leading Health Promotion into the 21st Century, meeting in Jakarta from 21 to 25 July 1997.
  19. Puska P‎ (2001) Health-related lifestyles are the key: round table discussion/Pekka Puska. Bulletin of the World Health Organization: the International Journal of Public Health 79: 985-998.
  20. Taket AR (1990) Making partners-intersectoral action for health. In: Proceedings and outcome of a joint working group on intersectoral action for health, Utrecht, 30 November-2 December 1988. The Hague, Ministry of Welfare, Health and Cultural Affairs.

Caribbean Faith-Based Organisations: Friend or Foe in the Fight against the Feminisation of HIV and AIDS in the Anglophone Caribbean

DOI: 10.31038/AWHC.2021441

Abstract

The feminisation of HIV and AIDS has become a worldwide phenomenon, and the Caribbean region has not been fortunate enough to be excluded. Caribbean females had 3-4 times higher infection rates than males up to a decade ago. Studies that focus on the contributing psychosocial factors to HIV risk in the Caribbean are limited. This narrative review showcases pivotal work which addresses the reciprocally connected responsibilities of patriarchy and religious practices and how they feed into the desolate reality of Anglophone Caribbean women. The relationship between these cultural issues in the Caribbean, using an anthropological lens, sets a platform for an investigation into HIV and AIDS. This paper seeks to encourage further research centred on the religious elements, which influence heterosexual relationships, and how these relationships are predisposed to potential HIV and AIDS risk. The ultimate goal of this study is to provide English- speaking Caribbean faith-based organisations, public health officials and policymakers a public stage to consider further policy implications for the staggering and disproportionate rates of HIV and AIDS between women and men.

Keywords

Anglophone Caribbean women, Faith-based organisations, Patriarchy, Feminisation of HIV and AIDS, Heterosexual relationships

Introduction

HIV and AIDS is an ongoing public health concern in the Caribbean community, with the second-highest HIV prevalence after Sub-Saharan Africa (Avert, 2020). Globally, there are almost equal infection rates among women and men. In Caribbean nation-states, like other countries, however, more women, as opposed to men, are particularly vulnerable to this epidemic: women account for approximately 53% of all reported HIV cases (UNAIDS, 2020). Currently, women, including transgender women, contract HIV disproportionally compared to the rates of men, and the gap continues to increase among certain groups (Avert, 2020). For example, in Trinidad and Tobago, HIV and AIDS rates are five times higher for girls than boys ages 15-19 (Pan American Health Organization (2011). These trends have initiated united cooperation between local and regional health and gender agencies to reverse the spread of this feminised disease within Caribbean territories.

Methodology

A comprehensive narrative review was conducted to identify research articles that explored the Feminization of the HIV and AIDS epidemic and the contributing role of Faith-Based Organisations in dealing with this infectious disease challenge in the Caribbean. The literature search also included current rates and trends of disease transmission according to gender within the Caribbean region. For this study, women were defined as cisgender and did not include women in the transgender community. This review included the analysis of peer-reviewed articles and official reports from international and regional public health agencies. Library databases were the primary tool used for the literature search. The World Health Organization, The Joint United Nations Programme on HIV/AIDS, The Pan American Health Organization and The United Nations Women Entity for Gender Equality and the Empowerment of Women websites were also used to access fact sheets and other pertinent data on HIV and AIDS.

Collection of the literature was done using the following search terms: “Faith-Based Organisations and HIV and AIDS,” “HIV and AIDS in the Caribbean,” “Women and HIV and AIDS,” and “Religion and HIV and AIDS.” All articles were evaluated for their relevance and applicability to the themes that were to be explored. A total of twenty-three (23) data sources were used for this literature review. Most of the articles selected were published within the last twenty years. An exception was made to include an article outside the specified period since the covered information is still relevant today. The findings were categorised into four different themes, which underscored the importance of addressing the Feminization of HIV and AIDS in the Caribbean and the role of religious organisations in ameliorating the situation.

Women and HIV Risk

Despite the continued recognition of women’s alarming HIV and AIDS case numbers, with their concomitant high-risk sexual practices, the perceived HIV risk can be best described as low to moderate. This low perception of women’s HIV risk can be attributed to multiple determinants, including generational knowledge, traditional practices, and misconceptions regarding safe sex behaviours (Charlery, 2005). Primarily, these cultural beliefs are responsible for driving unsafe sexual behaviours, which threaten many women’s physical and mental health. Because of this disconcerting truth, attending to HIV and AIDS within the Caribbean is vital by targeting female groups with the worst health outcomes. This public health matter will require a multi-sectoral approach to reduce the incidence of HIV among Caribbean women. The religious community plays a prominent role in Caribbean society and can be a chief ally in pursuing greater HIV awareness and well-being among the female fellowship.

Faith-based values and beliefs are at the heart of Caribbean culture, and they play an integral role in the ways people relate one to the other. Religious dogma also influences the attitudes and behaviours which govern these human interactions. Sometimes, these religious doctrines are viewed as a purposive extension and perpetuation of patriarchy: a means of advocating and maintaining social control. Soares (2005) elucidates, “This ideology of male dominance, which underlies society’s oppression of and discrimination against women, is often encouraged by social and cultural institutions such as the church [1]. “Socio-cultural perspectives as they relate to religious cosmology are therefore linked to gender inequity.

As part of the societal norms, gender disparities have become a driving force, integral to the feminisation of HIV and AIDS. To mitigate this harmful outcome, “Acknowledgement must be made of Caribbean gender politics and its obliteration of true female agency. The negative repercussions of cultural indoctrination on all women within a patriarchal system must also be given prominence” [2]. All persons are entitled to what Soares (2005) describes as “gender justice” [1]. [This is where] “the same rights, freedoms, opportunities, recognition, and respect for all women and men regardless of their position in society, race and colour identity, religious persuasion, ethnic origin, and sexual orientation” [are given]. Opportunities should be awarded to everyone in a utopian world, especially those traditionally dispossessed and disadvantaged by their life’s circumstances. Does religion, therefore, provide this space for espousing “gender justice,” or does it epitomise and propagate gender injustice?

The Role of Religion

Religions practised in the Caribbean such as Christianity, Hinduism, Islam, and Rastafarianism all have clearly defined positions on the gender issues raised in this discourse. Collectively, these religions add to the complexity of the problem involving HIV and AIDS and women. For this discussion, allusion will be principally made to Christianity as it is the most pervasive religion. The Holy Bible, in Isaiah 61:1, preaches that people should live their lives following the example of Jesus Christ, whose coming was “to proclaim liberty to the captives and to heal the broken-hearted.” These “captives” and “the broken-hearted” refer to the oppressed in the society, such as women, gay men, sex workers and the poor, all of whom are at high risk of HIV. Therefore, it seems logical that Christians should devote themselves to eradicating injustices meted out to these groups. Isaiah presents God’s message, “I love justice and hate oppression,” while another prophet warns that “injustice is unrighteous and sinful” [1]. On this premise, religious leaders should cry out against abhorrent acts of inequalities and discrimination against disenfranchised communities, and in this case, vulnerable and victimised women. The revered God is the epitome of love and would therefore want justice for all. The conflict lies in reconciling what the Holy Bible says and what the church preaches.

The machismo culture (masculinity) and marianismo culture (femininity) in the Caribbean aligns with Christian values and influences women’s exposure and vulnerability to HIV and AIDS. Marianismo (derived from the Virgin Mary) portrays the ideal woman as modest, pure, dependent, weak, acquiescent, vulnerable, and abstinent until marriage. In this sense, “femininity” implies that a woman must be innocent and self-sacrificing, placing the needs and desires of her husband before herself [3]. Gupta (2002) and PAHO (2002), as cited in Hem-Lee-Forsyth (2019), explained that marianismo requires “good” females to be Virgin Mary like, and to possess less information on matters related to sex, as more knowledge might be indicative of promiscuous activities or extramarital relations [3-5]. Christianity, which can act as a conduit of machismo, teaches that the man is the head of the home and the wife must submit to him. According to 1 Corinthians 11:3: “Christ is supreme over every man; the husband is supreme over his wife”.

The everyday living of “good” Christians often reflects this philosophy of male dominion over the subservient woman as part of the divine design. In cases of infidelity, domestic violence, and any abuse in the marriage, where men are the primary perpetrators, these acts are often described as “their [women’s] cross to bear;” spouses are encouraged to forgive and work through their differences, and mend the relationships [6]. Male privilege is yet again demonstrated as reigning supreme in the private and intimate lives of women. Gleeson, 2017, p. 12, questions whether “an all-male hierarchy [in the church] [even] capable of responding effectively to gendered violence?” if called on to provides an intervention [6]. Many couples, therefore, end up staying together “for richer or poorer, in sickness and in health, to love and to cherish, till death do [they] part,” although their relationships can potentially lead to the detriment of the women’s welfare. This case demonstrates that these types of social constructs, which put women in harm’s way, are seldom contested by religious organisations. It is heartening to see that Christians are becoming more progressive on the current surge of domestic abuse incidents and are encouraged to leave due to the lower stigma attached to divorce [6].

Despite the Caribbean’s religiosity, particularly among Christians who are proponents of monogamy, the Caribbean seems more tolerant of male promiscuity than female promiscuity. With that said, monogamy is the most apparent solution for HIV and AIDS prevention [7]. Some worshippers hold the religious belief that chastity until marriage guarantees disease prevention [8]. For Christian Catholics, engaging in sexual intercourse within the sanctity of marriage prohibits all contraceptive methods. Irrevocably, for those who heed this instruction, their HIV risk is increased, particularly if spouses are engaging in extramarital sexual relationships.

Similarly, male supremacy in the Caribbean Rastafarianism appears to be the order of the day; males are the physical and spiritual leaders of the household. Teachings in the Rastafarianism religion are derived from Christianity; many biblical references to wives submitting to their husbands are similar to Rastafarianism [9]. Some Muslims are strong supporters of the practice of polygamy. Only the first wife is recognised in Caribbean civil law, and the others are common-law wives. The lack of urgent attention paid to this polygamous practice by civil society and other interest groups contributes to the spread of HIV as there is no surety as to whether the husband and his wives will remain faithful. In the Caribbean, collectively, the tenets of these religions tend to preserve and even bolster gender bias; inadvertently, this actuality affects women’s health to a higher degree than their male counterparts.

Religion and Marginalised Groups

Religious groups have consensus on and have publicly lauded the prohibition of prostitution and homosexuality. Most English-speaking Caribbean countries have criminalised both; nonetheless, these “illegal acts” are still widespread with few or no convictions at all. However, it is common knowledge that several churchgoers overtly condemn and demonise any semblance of sex work or LGBTQIA+ orientation. In a one of its kind study done in Grenada on the views of the Grenadian faith-based community on HIV and AIDS, Gomez and Alexis-Thomas found that church members do not alienate these groups; instead, they offer advice and counselling in the hope that they change their “illegal,” “wrong” and “sinful” lifestyle [10].

In so far as HIV-risk taking behaviour is concerned, this is frowned upon by most religious communities. Inevitably, these organisations are faced with a predicament: on the one hand, there is a celebration of abstinence and fidelity, but on the other, there is a lack of compliance by devotees, thereby contributing to increased risk-taking practices in the general public. Although these religious sects have traditionally assumed crucial roles vis à vis education and social justice, discussions in this modern era on gender, sexual health and safe sex continue to be taboo- often deemed irreconcilable with most Christian beliefs. Nonetheless, the struggle for advocacy around these serious issues should be pursued. In a study, Cotton, Puchalski, Sherman et al., emphasised that religion could be a great source of solace for individuals living with HIV [11]. Within the study, most individuals belonged to a religious community; they credited their faith-based organisation to boost their self-esteem and optimism towards their future lives [11]. Although this study was conducted in the United States, lessons can be easily extrapolated in the Caribbean context, of which there is a dire need for redress.

It is undeniable that followers are impressed by religious influences on societal values and norms in everyday living. In Matthew 25:35-36, the Holy Bible stresses the importance of helping those individuals in need. To fulfil that obligation, religious organisations and their affiliates participate in service activities centred around serving underprivileged and dispossessed community members. However, as expounded previously, this practice does not transcend affairs related to gender and sexual health. In Gomez & Alexis-Thomas, the unfortunate actuality that came to the fore in that study is the Herculean task of obtaining buy-in from religious leaders to embark on health campaigns targeting sexual health matters [10].

The unswerving heterosexual thrust of marianismo and Christianity can be linked to the feminisation of HIV and AIDS in the Caribbean. At such an inopportune moment in history, the insistence on heteronormality, and the blatant denial and rejection of same-sex sexual orientation, provide a thriving environment for stigmatisation of lesbian and bisexual women. According to PAHO, this makes it difficult for women who have sex with women to access sexual health information and services, including appropriate barrier methods used for safer sex [3]. This resolute and myopic position on human sexuality within religion-based organisations presents an obvious quandary in striking a balance between the need to assist the public through sexual health education and doing it in such a way sans compromise of integrity regarding religious beliefs.

Perspectives from the Religious Communities

The religious community’s dilemma is being the champion for social justice and being the defenders of their faith. The Holy Bible says, “Do not be unequally yoked with unbelievers. For what partnership has righteousness with lawlessness; sin is lawlessness” (In 2 Corinthians 6:14).

For members of the Christian public, this passage suggests avoiding any association with unrighteous practices. While Christianity typically has a mission of service, education, and social justice, its followers are also required to uphold their faith without compromising the teachings of the Holy Bible.

For conservative Christians, in particular, participating in sexual health education presents a potential threat to their beliefs, teachings, and perspectives. According to a study conducted in Jamaica, there are faith-based initiatives to tackle the HIV and AIDS crisis in the country; however, these initiatives are not well-documented. Nevertheless, Christian establishments give support dedicated to sexual health education through their HIV and AIDS ministries. These services come in the form of psychosocial and family life counselling, health fairs, and seminars/workshops. While stigma and discrimination towards risky sexual behaviours are still prevalent in the Caribbean, these religious bodies respond to the loud cry to the cause by making provisions for disenfranchised groups within their communities [12].

In different country contexts, there is documented evidence that reinforces the fact that the church does sterling work in health promotion services. For example, in the United States, the Black church plays an essential role in offering health education programming to its membership. Austin and Harris examined the role of the Black congregation in transmitting health information, which included HIV and AIDS materials [13]. The study highlighted the benefits of bringing awareness to the community, including increased discussion among family members about trepidations regarding their health; and ensuring that communities are empowered to take personal responsibility for their holistic health care.

Historically, the Black church has been an indispensable source of general assistance to the African American community; in this regard, there is a greater likelihood that educational resources shared by church volunteer personnel will be more welcomed and trusted than similar resources presented by the external community healthcare workers. In addition, the church provides a safe and suitable site: multiple media can be employed to inform the flock about the different sexual health risks and the importance of screening for HIV and AIDS, and self-help groups can provide morale-boosting conversations around daily sexual health activities. Further, church settings and other community type centres are also less stigmatising than clinics, and the setting up of health centres can serve as testing or treatment centres [14]. Similarly, in the Caribbean, houses of religion can become the backbone of health and social support for members, providing well-needed resources on HIV and AIDS in their respective communities.

Acknowledging that faith-based organisations may be reluctant to engage in sexual health education, there may be other avenues to reduce the spread of HIV and AIDS among women. Several of the women in the Caribbean considered to be at high risk of HIV are sex workers. According to Sharpe & Pinto, some of these women are unemployed and are responsible for caring for their family members [15]. Religious organisations can indirectly assist these women through self-empowerment programs that educate and equip them to gain employment and subsequent financial security. These organisations can also implement social safety net programs to provide food security, housing, and financial aid for children and the elderly within vulnerable households. There are creative ways that faith-based organisations can alleviate the burden of the ongoing epidemic; this can be carried out in a manner that aligns with their beliefs and practices. Moreover, HIV and AIDS activists and other interest groups should not rule out the possibility of garnering attention from the religious community. On the contrary, these groups should foster meaningful relationships; engage in meaningful conversations with the religious communities; create healthy and happy societies.

In numerous capacities, Caribbean faith-based organisations have taken the mantle to assist communities with natural disasters, pandemics such as COVID-19, and other public health hurdles such as chronic and lifestyle diseases. Consequently, there are limited reasons to believe that the HIV and AIDS epidemic is any different: religious organisations do have a role in confronting the existence of HIV and AIDS. Organisations are constantly changing and evolving to meet the demands of society. Religious communities should boost efforts to help the most susceptible female populations in society. Undoubtedly, this will be a somewhat novel and challenging venture for most religious groups; however, with the proper guidance to execute community programs from public health institutions and non-profit organisations, this undertaking can indeed exist. With this combined stakeholder engagement, there will be positive outcomes when grabbling with the feminisation of HIV and AIDS.

Conclusion

Internationally, as The Joint United Nations Programme on HIV/AIDS [UNAIDS] and critical patrons strive to end the HIV and AIDS epidemic by 2030 aggressively, it is also of utmost importance to consider the feminisation of HIV and AIDS. In the Caribbean community, religious groups are significant partners and influencers; in this regard, their power of influence on the cultural practices of their people is second to none. Notably, Caribbean societies are matriarchal- women often lead households; furthermore, females play pivotal roles within the religious community. With prominent female leadership engagement within religious institutions, strategically, women are positioned to challenge gender norms and advocate for gender equality; this affirmative action will lead to an emphatic win: a reduction in the feminisation of HIV and AIDS.

According to the Kaiser Family Foundation Global Health Policy, approximately 50% of people living with HIV in the Caribbean have suppressed viral loads, below the global average of 59% [16-22]. This statistic indicates that Caribbean islands lag behind the rest of the world in guaranteeing equitable access to medication for blood viral load reduction in HIV patients. At this juncture, further scrutiny into discrepancies of viral load within the Caribbean compared to the rest of the world and viral load differences among genders is warranted.

This article mainly draws on resources from countries outside of the Caribbean region for comparisons and recommendations. There are limited regional analyses that focus on religion’s role in the fight against the feminisation of HIV and AIDS. Findings and recommendations on men who have sex with men and transgender women, both associated with the feminisation of HIV and AIDS in the Caribbean, have not been included in this manuscript. Considering both identities in the discussion on HIV and AIDS within religious organisations for future studies must be considered. Indisputably, apart from religious communities, there are many other communities providing opportunities for scholars to explore other pertinent and interconnected areas of HIV research to concentrate on the ongoing HIV epidemic. Anthropological factors, and their influence on HIV and AIDS, need to be a focal point of the exploration if there is any hope of reversing the feminisation of HIV and AIDS in Caribbean nations.

References

  1. Soares J (2005) Gender justice and the Christian mission. Journal of Religious Thought 57: 67-82.
  2. Hem-Lee-Forsyth S (2019) Carnival bacchanal culture and the silent HIV risk among female Caribbean professionals. International Journal of Public Health 11: 413-423.
  3. Pan American Health Organization. (2011). The UNGASS, Gender and Women’s Vulnerability to HIV/AIDS in Latin America and the Caribbean. PAHO.
  4. Gupta RG (2002) Vulnerability and resilience: Gender and HIV/AIDS in Latin America and the Caribbean.
  5. Hem-Lee-Forsyth S, Hunter C, McNab J, Ku C (2019) Culture and its impact on the feminisation of HIV and AIDS risk among Caribbean women. International Journal of Gender and Women’s Studies 7: 17-28.
  6. Gleeson H (2017) ‘Their cross to bear’: The Catholic women told to forgive domestic violence. ABC News Australia.
  7. Mount Holyoke, Roberts D, Reddock R, Douglas D, Reid S (2009) Sex, power and taboo: Gender and HIV in the Caribbean and beyond. Kingston: Ian Randle Publishers.
  8. Voelker R (2005) Women shoulder growing HIV/AIDS burden. JAMA 293: 281-282. [Crossref]
  9. Lake O (1994) The Many Voices of Rastafarian Women: Sexual Subordination in the midst of Liberation. New West Indian Guide 68: 235-257.
  10. Gomez A, Alexis-Thomas C (2010) HIV/AIDS: perceptions of the Grenadian faith-based community. West Indian Medical Journal 59: 356-361. [Crossref]
  11. Cotton S, Puchalski CM, Sherman SN, et al. (2006) Spirituality and religion in patients with HIV/AIDS. Journal of general internal medicine 21: S5-13. [Crossref]
  12. Muturi N (2008) Faith-Based Initiatives in Response to HIV/AIDS in Jamaica. IJOC 108-131.
  13. Austin S, Harris G (2011) Addressing Health Disparities: The Role of an African American Health Ministry Committee. Social Work in Public Health 26: 123-135. [Crossref]
  14. Pillay Y (2011) The Role of the Black Church, the Barbershop/Beauty Salon, and Digital Communication to Support African American Persons Living With HIV/AIDS. Journal of Creativity in Mental Health.
  15. Sharpe J, Pinto S (2006) The Sweetest Taboo: Studies of Caribbean Sexualities; A review essay. Journal of Women in Culture and Society 32: 247-274.
  16. King James Bible (2021) King James Bible Online. The Global HIV/AIDS Epidemic. Kaiser Family Foundation.
  17. Francis C, Lewis-Agard N (2020) Faith Based Efforts in the Caribbean to Combat Discrimination Based on Sexual Orientation and Gender Identity. Arcus Foundation.
  18. Lazarus L (2012) This is a Christian Nation: Gender and Sexuality in Processes of 9 Constitutional and Legal Reform in Jamaica. Social and Economic Studies 61 (3) Special issue on women’s health and rights in select Caribbean countries (September 2012).
  19. Pan American Health Organisation (2002) Gender and HIV/AIDS in Latin America and the Caribbean. [Fact Sheet].
  20. Reed CS (2014) Sexual & Reproductive Health of Dutch Afro-Caribbean Women: An Analysis of Culture, Reproductive Statistics and Black Female Sexuality.
  21. Susser I, Stein Z (2000) Public health matters: Culture, sexuality, and women’s agency in the prevention of HIV/AIDS in Southern Africa. American Journal of Public Health 90: 1042-1048.
  22. The United Nations Entity for Gender Equality and the Empowerment of Women. (2015). Facts and figures: HIV and AIDS. US Agency for International Development.

The Role of Interleukin-1β in the Pathogenesis and Treatment of Acute Pericarditis

DOI: 10.31038/JCCP.2021422

Abstract

Acute pericarditis is characterized by severe inflammation of the fibrous and serous pericardial membranes covering the heart. It is caused by multifactorial conditions, such as systemic diseases, autoimmune inflammatory diseases, malignant tumours, bacterial and viral infections, including SARS-CoV-2. In Europe, most cases of acute pericarditis are idiopathic (80-90%), and may follow viral infections. In sub-Saharan Africa, the leading cause of effusive and constrictive pericarditis is tuberculous pericarditis, secondary to HIV/AIDS in about 70% of patients. Approximately, 30% of cases of acute pericarditis are recurrent despite the standard of care, and about 25-30% present as pericardial effusion which may lead to cardiac haemodynamic compromise (cardiac tamponade). Stepwise treatment of consists of aspirin, or any other non-steroidal anti-inflammatory drugs, colchicine, and corticosteroids. Interleukin-1 is a master proinflammatory cytokine existing in two isoforms, IL-1α and IL-1β, and the latter is the most studied, and is implicated in several autoinflammatory diseases, autoimmune diseases, metabolic syndromes, cardiovascular disease, including acute pericarditis. Anakinra is a recombinant, nonglycosylated human interleukin-1 receptor antagonist that competes and inhibits the effects of IL-1α and IL-1β, thus reducing their systemic inflammatory effects. Treatment with anakinra has been shown to be effective in the control of recurrent acute pericarditis in patients who are resistant to colchicine and corticosteroid-dependent. Additionally, treatment with anakinra results in more patients tapering or discontinuing corticosteroids, with no further recurrences of acute pericarditis. Furthermore, treatment with anakinra has been shown to prevent or reverse constrictive pericarditis. Rilonacept effectively acts as an “IL-1 trap” by binding to circulating IL-1α and IL- 1β molecules, inhibiting the downstream activation of IL-1β inflammatory cascade (Table 1).

Table 1: Causes of acute pericarditis and recurrent pericarditis.

Idiopathic
Viral infections

Adenovirus, Coxsackie virus A and B,  Echovirus, Epstein-Barr virus, Influenza, Mumps, HIV, SARS-CoV-2

Bacterial infection

Mycobacterium tuberculosis, Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Legionella, Listeria, Meningococcus, Gonococcus, Salmonella, Syphilis

Fungal infections

Aspergillosis, Blastomycosis, Coccidioidomycosis, Histoplasmosis, Candida

Parasitic infections

Echinococcus granulomatosis, Entamoeba histolitica

Protozoal infection

Toxoplasmosis gondii

Chest trauma
Irradiation
Cardiovascular disease

Chronic heart failure

Acute myocardial infarction

Post-myocardial infarction (Dressler syndrome)

Aortic dissection

Cardiac surgery, post-pericardiotomy syndrome

Cardiac procedures, catheterization, post-pacemaker insertion

Neoplastic diseases

Primary: mesothelioma, angiosarcoma

Metastatic: lung, breast, bone, lymphoma, leukaemia, melanoma

Collagen vascular diseases

Rheumatoid arthritis, Systemic lupus erythromatosus, Scleroderma, Sjögren syndrome, Ankylosing spondylitis, Wegener granulomatosis, Behçet’s syndrome, Dermatomyositis

Infiltrative diseases

Sarcoidosis, Amyloidosis

Metabolic diseases

Uraemia, Hypothyroidism (myxedema), Gout

Drugs

Hydralazine, Minoxidil, Methysergide, Penicillin, Doxorubicin, Phenytoin, Procainamide, Sodium cromoglycate

Autoinflammatory diseases

Familial Mediterranean fever, Cryopyrin-associated periodic syndrome

Chylopericardium

Treatment with rilonacept has been shown to significantly relieve pain and other symptoms of pericarditis, and to rapidly resolve recurrent pericarditis. Additionally, rilonacept led to tapering or discontinuation of corticosteroids. Interleukin-1β antagonists should be initiated early in the course of acute pericarditis in order to avert the dreaded complications of acute pericarditis, such as recurrent pericarditis, tamponade, and constrictive pericarditis.

Keywords

Acute pericarditis, Anakinra, Colchicine, Interleukin-1, Interleukin-1 inhibitors

Introduction

Acute pericarditis is characterized by severe inflammation of the fibrous and serous pericardial membranes covering the heart [1,2]. It is caused by multifactorial conditions, such as systemic diseases, autoimmune inflammatory diseases, connective vascular diseases, neoplastic tumours, bacterial, fungal, and viral infections [3-6]. However, in Europe and North America, most cases of pericarditis are idiopathic (80-90%) [6], and may follow viral infection. In sub-Saharan Africa, the leading cause of chronic pericarditis is opportunistic tuberculous pericarditis (70%) [7,8], secondary to HIV/AIDS in about 70% of patients [8-11]. Recently, acute and recurrent pericarditis has been reported to be associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [12-17].

Approximately, 20-30% of cases of acute pericarditis are recurrent despite the standard of care (SoC) [1,3,18-22], and about 25-30% present as pericardial effusion which may lead to cardiac tamponade [3,4,12,23-25]. Cardiac tamponade is a life-threatening condition resulting in compression of the heart, reduced cardiac filling, haemodynamic compromise, and heart failure [25,26]. Constrictive pericarditis is another ominous complication of acute pericarditis [27,28]. It occurs in about 9% of patients with acute pericarditis, and may require pericardiectomy [29], which is lumbered by 5%-10% perioperative mortality [30].

Treatment of pericarditis is challenging, recurrent pericarditis with effusion is frequent, despite treatment with the standard of care (SoC). The stepwise treatment acute pericarditis based on the 2015 European Society of Cardiology guidelines for the management of recurrent pericarditis [1], consists of aspirin, or any other non-steroidal anti-inflammatory drugs (NSAIDs), such as ibrufen, indomethacin, and naproxen; colchicine; and corticosteroids [6,18-22,31-33]. At the top of the ladder treatment, azathioprine, and intravenous immunoglobulins may be added if symptoms persist, or if patients develop complications, such as recurrent pericarditis, and effusive constrictive pericarditis. However, some of the patients become unresponsive to the SoC [34,35]. About 5% of the patients despite treatment with standard dosages of aspirin or NSAIDs, colchicine, and prednisone continue to complain of symptoms, or have recurrent pericarditis with effusion. This sub-group of patients is resistant to colchicine and azathioprine, and become corticosteroid-dependent [36-41]. They require innovative therapies, such as IL-1β inhibitors (anakinra, or rilonacept) which block the inflammatory cascade implicated in pathogenesis of acute pericarditis [42,43].

Interleukin-1 Family

The interleukin-I (IL-1) family is ranked at the top of the hierarchy of innate immune signaling, and is comprised of 11 soluble molecules and 10 receptors [44-46]. It is divided into three subgroups, depending on the IL-1 consensus sequence, and the signaling receptor chain. It include cytokines with agonistic activity, such as IL-1α, IL-1βb, IL-18, IL-33, IL-36a, IL-36b, and IL-36g; receptors antagonists, including IL-1Ra, IL-36Ra, and IL-38, and an anti-inflammatory cytokine IL-37 [44-47]. The IL-1 family signaling is via 10 receptors, coreceptors, decoy receptors, and inhibitory receptors with similar and different immunopathological effects [48,49]. Interleukin-1 receptors, and decoy receptors are potential targets for blockade, and have been exploited in the development of several biologics for the treatment of several diseases, including cardiovascular diseases, and cancer.

Interleukin-1 and its most related family members IL-18, and IL-33 play different roles in innate immunity and inflammation in response to microbial, and environmental insults. Interleukin-18 mediates mostly type 1 innate immunity, and inflammatory responses [50], whereas, IL-33 plays a central role in type 2 innate and adaptive immunity, and inflammation [51]. IL-33 is an ‘alarmin’ cytokines secreted by epithelial cells, in response to microbial infections, cell death, necrosis, mechanical stress, and trauma [52], and plays a central role in the pathogenesis of eosinophilic asthma [52-55], and chronic rhinosinusitis with nasal polyps [56-59]. IL-1β and IL-18 are the most studied family members [44,45], and IL-1β has emerged as the most promising therapeutic target for the treatment of several autoimmune, and inflammatory diseases, including cardiovascular diseases [60,61].

Interleukin-1β

Interleukin-1 is a master pro-inflammatory cytokine which exists in two isoforms, including IL-1α, and IL-β, with proinflammatory and pyogenic properties [62,63]. It is produced principally in monocytes and macrophages, but also in neutrophils.  IL-1β is a key up-regulator of inflammatory mediators, such as cyclo-oxygenase-2 (COX-2), and prostaglandins. Interleukin-1β, and the inflammatory mediators it induces for secretion are responsible for the inflammation, hyperaemia, hyperesthesia, and oedema characteristic of acute pericarditis [60,63-66]. IL-1β production and secretion is stimulated by NLRP3 inflammasome, pathogen-associated molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs), and other inflammatory cytokines, such a TNFβ, IL-8, and in an autocrine fashion by IL-1β [67]. NLRP3 (NACHT LRR and PYD domains-containing protein 3) plays a very important role in the production of IL-1β and IL-18 from their precursor immature forms [68,69]. Interleukin-1β is produced as a 269-AA precursor protein, and is processed by caspase-1 activated in the inflammasomes into its mature active form [70-73].

Interleukin-1β signaling is via two surface receptors, IL-1R1, and IL-1 type 2 receptor (IL-1R2), a decoy receptor. IL-1 binds to IL-1R1, which requires formation of a heterodimer with IL-1 type 3 receptor (IL-1R3) before binding [74]. Subsequently, MyD88 (myeloid differentiation factor 88) binding triggers a proinflammatory signaling via a cascade of phosphorylation resulting in activation of NF-kB (nuclear factor-kB) [74,75]. NF-kB translocates into the nucleus, henceforth, promoting transcription and translation of several proinflammatory genes, especially for the precursors of IL-1β, and IL-18, as well as components of the NLRP3 inflammasome [75]. Interleukin 1β and its receptors, coreceptor, and decoy receptor are favourable therapeutic targets in cardiovascular diseases [76-78], including acute and recurrent pericarditis [64-67].

Anakinra

Anakinra (Kineret; Swedish Orphan Biovitrum, Stockholm, Sweden) is a recombinant, nonglycosylated human interleukin-1 receptor 1 antagonists that competes and inhibits the effects of IL-1α and IL-1β, thus reducing their systemic inflammatory effects. It is approved for the treatment of several diseases, including rheumatoid arthritis, cryopyrin-associated periodic syndrome (CAPS), a multisystematic IL-1β-mediated disease due to a gain of function in NLRP3, and neonatal-onset multisystem inflammatory disease (NOMID). It is given as 100 mg subcutaneouly once daily. Anakinra when administered early has been shown to be very effective in in the treatment of colchicine resistant, and corticosteroid-dependent recurrent pericarditis [79,80]. Treatment with anakinra has been shown to be effective in the control of symptoms due to acute pericarditis, and in preventing recurrent pericarditis, and pericardial effusion [79-81], and reversing constrictive pericarditis [82]. Additionally, treatment with anakinra results in more patients tapering or discontinuing corticosteroids, with no further recurrences of acute pericarditis. Furthermore, treatment with anakinra has been shown to prevent or reverse constrictive pericarditis. Adverse events related to treatment with anakinra are listed in Table 2.

Table 2: Anakinra adverse effects.

Injection-site reaction, redness and swelling
Arthralgia
Myalgia
Mild fever
Hives
Tiredness or weakness
Headache
Stomachache
Nausea, vomiting
Diarrhoea
Swelling of face, lips, tongue, and eyelids
Unusual bruising or bleeding
Infections, nasopharyngitis, sore throat
Neutropenia
Hypereosinophilia
Thrombocytopenia
Elevation of transaminases
Optic neuritis (rare)
Diverticulitis perforation (rare)

Rilonacept

Rilonacept  (Arcalyst; Regeneron Phamaceuticals, Tarrytown, NY) is a dimeric fusion protein that consists of ligand binding domains of the extracellular portions of the IL-1 receptor component (IL-R1), and the IL-1 receptor accessory protein that is linked to the Fc portion of human IgG1. Rilonacept effectively act as an “IL-1 trap” by binding to circulating IL-1α and IL- 1β molecules, effectively blocking the engagement of IL-1β to pro-inflammatory cell surface receptors, and inhibiting the downstream activation of IL-1β inflammatory cascade. It is approved for the treatment of CAPS, and is administered as a loading dose of 320 mg subcutaneously once, then followed by 160 mg every 2 weeks. Treatment with rilonacept has been shown to significantly relieve pain and other symptoms of pericarditis, and to rapidly resolve recurrent pericarditis [83]. Additionally, rilonacept led to tapering or discontinuation of corticosteroids [83]. Notably, rilonacept has been demonstrated to reverse constrictive pericarditis [83]. Adverse effects of rilonacept include injection-site reaction, and neutropnea with danger of susceptibility to infections. Rilonacept was approved by the US Food and Drug Administration (FDA) in March 2021 for the treatment of pericarditis, in patients aged 12 years and older.

Interleukin-1 Antagonists And Covid-19

Interleukin-1 blockade causes neutropnenia and susceptibility to infection. However, it seems that anakinra and rilonacept do not influence the epidemiology, and clinical outcome of SARS-CoV-2. Moreover, several studies have reported that anakinra is associated with reduced mortality and need for mechanical ventilation, and has a good safety profile in patients with SARS-CoV-2 [84-90].

Conclusion

Acute pericarditis is characterized by severe inflammation of the fibrous and serous pericardial membranes covering the heart. The stepwise treatment of acute pericarditis consists of aspirin or NSAIDs, colchicine, and prednisone. About 5% of the patients with acute pericarditis develop resistance to colchicine, and are corticosteroid-dependent. Interleukin-1β antagonists, such as anakinra and rilonacept should be initiated early in the course of acute pericarditis in order to avert the troublesome complications of acute pericarditis, such as recurrent pericarditis, cardiac tamponade, and constrictive pericarditis.

References

  1. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. (2015) 2015 ESC guidelines for the diagnosis and management of pericardial diseases. Eur Heart J 36: 2921-2964. [crossref]
  2. Tombetti E, Mulè A, Tamanini S, Matteuci L, Negro E, et al. (2020) Novel pharmacotherapies for recurrent pericarditis; Current options in 2020. Curr Cardiol Rep 22: 59. [crossref]
  3. Schwier NC, Hale GH, Davies ML (2017) Treatment of adults with idiopathic recurrent pericarditis: novel use of immunotherapy. Pharmacotherapy 37: 305-318. [crossref]
  4. Brucato A, Imazio M, Cremer PC, Adler Y, Maisch B, et al. (2018) Recurrent pericarditis: still idiopathic? The pros and cons of a well-honoured term. Intern Emerg Med 13: 839-844. [crossref]
  5. Chang SA (2017) Tuberculous and infectious pericarditis. Cardiol Clin 35: 615-622. [crossref]
  6. Andreis A, Imazio M, Casula M, Avondo S, Brucato A (2021) Recurrent pericarditis: an update on diagnosis and treatment. Intern Emerg Med 1-8. [crossref]
  7. Imazio M, Gaita F, LeWinter M (2015) Evaluation and treatment of pericarditis: a systemic review. JAMA 314: 1498-1506. [crossref]
  8. Mayosi BM, Wiysonge CS, Ntsekhe M, Volmink JA, Gumedze P, et al. (2006) Clinical characteristics and initial management of patients with tuberculous pericarditis in the HIV era: the investigation and management of pericarditis in Africa (IMP Africa) registry. BMC Infect Dis 6:2. [crossref]
  9. Ntsekhe M, Mayosi BM (2009) Cardiac manifestation of HIV infection: An African perspective. Nat Clin Pract Cardiovasc Med 6: 120-127. [crossref]
  10. Abubaker U, Adeoye PO, Adebo OA, Adegboye VO, Kesieme EB, et al. (2011) Pattern of pericardial diseases in HIV-positive patients at University College Hospital, Ibadan, Nigeria. HIV Medicine 12: 2.
  11. Noubiap JJ, Agbor VN, Ndoadoumgue AL, Nkeck JN, Kamguia A, et al. (2018) Epidemiology of pericardial disease in Africa: a systemic scoping review. BMJ Heart 105.
  12. Blagojevic NR, Bosnjakovic D, Vukomanovic V, Arsenovic S, Lazic JS, et al. (2020) Acute pericarditis and severe acute respiratory syndrome coronavirus 2: Case report. Int J Infect Dis 101: 180-182. [crossref]
  13. Farina A, Uccello G, Spreafico M, Bassanelli G, Savonitto S (2020) SARS-CoV-2 dtected in the pericardial fluid of a patient with cardiac tamponade. Eur J Intern Med 76: 100-1001. [crossref]
  14. Fox K, Prokup JA, Butson K, et al. (2020) Acute effusive pericarditis: A late complication of COVID-19. Cureus 12: e9074. [crossref]
  15. Kumar R, Kumar J, Daly C, Edroos SA (2020) Acute pericarditis as a primary presentation of COVID-19. BMJ 13.
  16. Tung-Chen Y (2020) Acute pericarditis due to COVID-19 infection: An undiagnosed disease? Med Clin (Engl Ed) 155: 44-45. [crossref]
  17. Fajay R, Belkhayat C, Bouchlarhem A, El Aidouni G, Bkiyar H, et al. (2021) Acute pericarditis revealing COVID-19 infection. Case report. Annal Med Surg 62: 225-227. [crossref]
  18. Imazio M, Brucato A, Cemin R, Ferrua S, Maggiolini S, et al. (2013) A randomized trial of colchicine for acute pericarditis. N Engl J Med 369: 1522-1528. [crossref]
  19. Imazio M, Brucato A, Cemin R, Ferrua S, Belli R (2011) CORP (Colchicine for Recurent Pericarditis) Investigators. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med 155: 409-414. [crossref]
  20. Imazio M (2014) Treatment of recurrent pericarditis. Revista Espanola de Cardiologia 67: 345-348.
  21. Tombetti E, Giani T, Brucato A, Cimaz R (2019) Recurrent pericarditis in children and adolescents. Front Pediatr 7: 419. [crossref]
  22. Chiabrando JG, Bonaventura A, Vecchie A, Wohlford GF, Mauro AG, et al. (2020) Management of acute and recurrent pericarditis: JACC state-of-the-art review. J Am Coll Cardiol 75: 76-92. [crossref]
  23. Sagristà-Sauleda J, Mercé AS, Soler-Soler J (2011) Diagnosis and management of pericardial effusion. World J Cardiol 3: 135-143. [crossref]
  24. Imazio M, Mayosi BM, Brucato A, Markel G, Trinchero R, et al. (2010) Triage and management of pericardial effusion. I Cardiovasc Med 11: 928-935. [crossref]
  25. Imazio M, Adler Y (2013) Management of pericardial effusion. Eur Heart J 34: 1186-1197.
  26. Ristic AD, Imazio M, Alder Y, Anastasakis A, Badano LP, et al. (2014) Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 35: 2279-2284. [crossref]
  27. Matshela MR (2017) Constrictive pericarditis: prevention and treatment. E-J Cardiol 15:24.
  28. Maisch B (2018) Management of pericarditis and pericardial effusion, constrictive and effusive-constrictive pericarditis. Herz 43: 663-678. [crossref]
  29. Yadav NJ, Siddique MS (2021) Constrictive pericarditis. StatPearls. [crossref]
  30. Khandaker MH, Sahaff HV, Greason KL, Anavekar NS, Espinosa RE, et al. (2012) Pericardiectomy vs medical management in patients with relapsing pericarditis. Mayo Clin Proc 87: 1062-1070. [crossref]
  31. Dauphin C, Merlin E, Chalard A, Trésorier R, Lusson J, et al. (2016) Recurrent pericarditis: current challenges and future prospects. Res Reports Clin Cardiol 7: 99-108.
  32. Imazio M, Bobbio M, Cecchi E, Demarie D, Pomari F, et al. (2005) Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (Colchicine for Recurrent pericarditis) trial. Arch Intern Med 165: 1987-1991. [crossref]
  33. Imazio M, Belli R, Brucato A, Cemin R, Ferrua S, et al. (2014) Efficacy and safety of colchicine for the treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet 383: 2232-2237. [crossref]
  34. Soler-Soler J, Sagristà-Sauleda J, Permanyer-Miralda G (2004) Relapsing pericarditis. Heart 90: 1364-1368. [crossref]
  35. Imazio M, Trinchero R, Shabetai R (2007) Pathogenesis, management, and prevention of recurrent pericarditis. J Cardiovasc Med (Hagerstown) 8: 404-410. [crossref]
  36. Spodick DH (2003) Acute pericarditis: current concepts and practice. JAMA 289: 1150-1153. [crossref]
  37. Little WC, Freeman GL (2006) Pericardial disease. Circulation 113: 1622-1632. [crossref]
  38. Imazio M, Brucato A, Trinchero R, Adler Y (2009) Diagnosis and management of pericardial disease. Nat Rev Cardiol 6: 743-751. [crossref]
  39. Imazio M, Spodick DH, Brucato A, Trinchero R, Adler Y (2010) Controversial issues in the management of pericardial disease. Circulation 121: 916-928. [crossref]
  40. Cremer PC, Kumar A, Kontzias A, Tan CD, Rodriguez ER, et al. (2016) Complicated pericarditis: understanding risk factors and pathophysiology to inform imaging and treatment. J Am Coll Cardiol 68: 2311-2328. [crossref]
  41. Lazaros G, Antonopoulos AS, Antonatou K, Skendros P, Ritis K, et al. (2020) Hydroxychloroquine for colchicine-resistant glucocorticoid-dependent idiopathic recurrent pericarditis: a pilot observational study. In J Cardiol 311: 77-82. [crossref]
  42. Lazaros G, Anthonatou K, Vassilopoulos D (2017) The therapeutic role of interleukin-1 inhibition in idiopathic recurrent pericarditis: current evidence and future challenges. Front Med (Lausanne) 4: 78. [crossref]
  43. Brucato A, Emmi G, Cantarini L, Di Lenarda A, Gattorno M, et al. (2018) Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism. Emerg Med 13: 475-489. [crossref]
  44. Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27: 519-550. [crossref]
  45. Dinarello CA (2017) Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev 281: 8-27. [crossref]
  46. Dinarello CA (2019) The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol 15: 612-632. [crossref]
  47. Martovani A, Dinarello CA, Molgora M, Garlanda C (2019) Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity Rev. [crossref]
  48. Dinerallo C, Arend W, Sims J, Smith D, Blumberg H, et al. (2010) IL-1 family nomenclature. Nat Immunol 11: 973. [crossref]
  49. Garlanda C, Dinarello CA, Mantovani A (2013) The interleukin-1 family: back to the future. Immunity 39: 1003-1018. [crossref]
  50. Kaplanski G (2018) Interleukin-18: Biological properties and roles in disease pathogenesis. Immunol Rev 281: 138-153. [crossref]
  51. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, et al. (2005) IL-33, an interleukin-1-like cytokine that signals via IL-1 receptor related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479-490. [crossref]
  52. Borish L, Steinke JW (2011) Interleukin-33 in asthma: How big of a role does it play? Curr Allergy Asthma Rep 11: 7-11. [crossref]
  53. Wang Y, Wang L, Hua S (2017) Interleukin-33 in children with asthma: A systemic review and meta-analysis. Allergol Immunopathol (Madr) 45: 387-392. [crossref]
  54. Ding W, Zou G-L, Zhang W, Lai X-N, Chen H-W, et al. (2018) Interleukin-33 its emerging role in allergic diseases. Molecules 23: 1665. [crossref]
  55. Syabbalo N (2021) The role of alarmin cytokines in the pathogenesis of severe uncontrolled asthma. Ann Clin Med Res 2: 1022.
  56. Schleimer RP (2017) Immunopathogenesis of chronic rhinosinusitis and nasal polposis. Annu Rev Pathol 12: 331-357.
  57. Kim DK, Jin HR, Eun KM, et al. (2017) The role of interleukin 33 in chronic rhinosinusitis. Thorax 72: 635-645. [crossref]
  58. Sehmi R (2017) Role of interleukin 33 in chronic rhinosinusitis. Thorax 72.
  59. Zhang L, Jiang L-L, Cao Z-W (2017) Interleukin-33 promotes the inflammatory reaction in chronic rhinosinusitis with nasal polyps by NF-kB signaling. Eur Rev Med Pharmacol Sci 21: 4501-4508. [crossref]
  60. Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117: 3720-3732. [crossref]
  61. Dinarello CA (2009) Interleukin-1 beta and the autoinflammatory disease. N Engl J Med 360: 2467-2470. [crossref]
  62. Abbate R, Trankle CT, Buckley LF, Lipinski MJ, Appleton D, et al. (2020) Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment-elevation myocardial infarction. J Am Heart Assoc 9: e014941. [crossref]
  63. Dinarello CA, Anna S, van der Meer J (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11: 633-652. [crossref]
  64. Brucato A, Emmi G, Cantarini L, et al. (2018) Management of idiopathic recurrent pericarditis in adults and children: a role for IL-1 receptor antagonism. Int Emerg Med 13: 475-489. [crossref]
  65. Buckley LF, Viscusi MM, Van tassel BW, Abbate A (2018) Interleukin-1 blockade for the treatment of pericarditis. Eur Heart J Cardiovasc Pharmacother 4: 46-53. [crossref]
  66. Emmi G, Urban ML, Imazio M, et al. (2018) Use of interleukin-1 blockers in pericardial and cardiovascular disease. Curr Cardiol Rep 20: 61. [crossref]
  67. Picco P, Brisca G, Traverso F, Loy A, Gattorno M, et al. (2009) Successful treatment idiopathic recurrent pericarditis in children with interleukin-1 receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthritis Rheum 60: 264-268. [crossref]
  68. Hoffman HM, Gregory SG, Mueller JL, Tresiettas M, Broide DH, et al. (2003) Fine structure mapping of CIAS1: identification of an ancenstral haplotype and a common FCAS mutation, L353P. Human Genet 112: 209-216. [crossref]
  69. Karasawa T, Takahashi M (2017) Role of NLRP3 inflammasomes in atherosclerosis. J Atherosclerosis Thrombosis 24: 443-451. [crossref]
  70. March CJ, Mosley B, Larsen A, Cerretti DP, Braedt G, et al. (1985) Cloning, sequence and processing of two distinct human interleukin-1 complementary DNAs. Nature 15: 641-647. [crossref]
  71. Martinon F, Burns K, Tschopp J (2003) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol Cell 10: 417-426. [crossref]
  72. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, et al. (2004) NALP3 forms an IL-1beta-processing inflammasome with increased activity in muckle-wells autoinflammatory disorder. Immunity 20: 319-325. [crossref]
  73. Amin J, Boche D, Rakic S (2017) What do we know about the inflammasome in human? Brain Pathol 27: 192-194. [crossref]
  74. Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, et al. (2020) Interleukin-1 and the inflammasome as a therapeutic target in cardiovascular disease. Circ Res 126: 9. [crossref]
  75. Brikos C, Wait R, Begum S, O’Neill LA, Saklatvala J (2007) Mass spectrometric analysis of the endogenous type 1 interleukin-1 (IL-1) receptor signaling complex formed after IL-1 binding identifies IL-1RAcP, MyD88, and IRAK-4 as the stable components. Mol Cell Proteomics 6: 1551-1559. [crossref]
  76. Toldo S, Abbate A (2018) The NLRP3 inflammasome in acute myocardial infarction. Nat Rev Cardiol 15: 203-214. [crossref]
  77. Toldo S, Mauro AG, Cutter Z, Abbate A (2018) Inflammasome, pyroptosis, and cytokines in myocardial ischaemia-reperfusion injury. Am J Physiol Circ Physiol 315: H1553-H1568. [crossref]
  78. Zhou W, Chen C, Chen Z, Liu L, Jiang J, et al. (2018) NLRP3: A novel mediator in cardiovascular disease. J Immunol Res 2018: 5702103. [crossref]
  79. Basker S, Klein AL, Zeft A (2016) The role of IL-1 receptor antagonist (anakinra) in idiopathic recurrent pericarditis: A narrative review. Cardiol Res Pract 7840724.  [crossref]
  80. Chiabrando JG, Bonaventura A, Vecchié A, et al. (2020) Management of acute and recurrent pericarditis. JACC state-of-art review. J Am Coll Cardiol 75: 76-92. [crossref]
  81. Brucato A, Emmi G, Cantarini L, Di Lenarda A (2018) Management of idiopathic recurrent pericarditis in adults and children: a role of IL-1 receptor antagonism. Int Emerg Med 13. [crossref]
  82. Lazaros G, Tousoulis D (2020) Interleukin-1 inhibition with anakinra: a valuable ally to reverse constrictive pericarditis? Heart 106: 1540-1542.
  83. Klein AL, Imazio M, Cremer P, Brucato A, Abbate A, et al. (2021) Phase 3 trial of interleukin-trap rilonacept in recurrent pericarditis. N Engl J Med 384: 31-41. [crossref]
  84. Pontali E, Volpi S, Antonucci G, Castellaneta M, Buzzi D, et al. (2020) Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. J Allergy Clin Immunol 146: 213-215. [crossref]
  85. Aouba A, Baldolli A, Geffray L, Verdon R, Bergot E, et al. (2020) Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Ann Rheum Dis 2020. [crossref]
  86. Dimopoulos G, de Mast Q, Markou N, Theodorakopoulou M, Komnos A, et al. (2020) Favorable anakinra responses in severe Covid-19 patients with secondary hemophagocytic lymphohistiocytosis. Cell Host Microbe 2020. [crossref]
  87. Navarro-Millán I, Sattui S, Lakhanpal A, Zisa D, Siegel C, et al. (2020) Use of anakinra to prevent mechanical ventilation in severe COVID-19: a case series. Arthritis Rheumatol. [crossref]
  88. Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, et al. (2020) Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol 2020.
  89. Kooistra EJ, Waalders NJB, Grondman I, Jassen NAF, de Nooijer AH, et al. (2020) Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study. Critical Care 24: 688. [crossref]
  90. Pasin L, Cavalli G, Navalesi P, Sella N, Landoni G, et al. (2021) Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. Eur J Intern Med 86: 34-40. [crossref]

Towards an Active Aging Society Based on Information and Communication Technology

DOI: 10.31038/ASMHS.2021521

 

With the development of medicine and technology, the life expectancy of people, nowadays, is getting longer than several decades ago. Aging society is progressively emerging. More and more nations in the world have steadily moved towards an aging society or even a super-aged society. Obviously, the arrival of the Tsunami of the Aged people could result in national vibrations at various levels that eventually would have a major impact upon the global economy, society and politics.

“Aging” is not mainly a physiological process, but also a social and cultural manner. Aging is traditionally regarded as a physiological development with biological function and physical system progressively failure. However, it is ordinarily accompanied by changes in mental and social conditions. In addition to the phenomenon of aging that occurs inside the individual, the stimulus of the external environment also affects the speed and level of aging. The World Health Organization (WHO) has proposed the concept of “active aging” in its 2002 Report of Active Ageing: A Policy Framework. This landmark document drew attention to:

the fact that population aging was the product of two converging trends: more and more people living to be old at the same time dramatic decreases were occurring in fertility rates; that population aging was to occur in both the developed and the developing worlds; and that if it was to be a positive experience for countries and individuals, “longer life must be accompanied by continuing opportunities for health, participation and security” [1].

Essentially, it is derived from the concept of successful aging and has increasingly developed as productive aging and healthy aging. The goal is to build a society more compatible with the increase in the elderly population and the advent of the aging society. According to the widely accepted WHO definition of active aging, it is the process of optimizing opportunities for health, participation, and safety in order to promote the quality of life of people in old age. The definition is echoing the WHO’s definition of health, a state of complete physical, mental, and social well-being. This has ultimately become the main reference framework for many international organizations and countries around the world to formulate health policies for the elderly.

Today, entering the information age, the overall life and behavior patterns of human beings have correspondingly been profoundly affected by cyber power. The invention of computers, the use of the internet, the popularization of tablets and smartphones, and internet usage and so on is evenly connected to the lives of the elderly. Surprisingly and beyond anyone’s imagination, elder people are affected by the internet as much as the young generations do. Based on empirical research findings that through the use of information technology could not only shorten the unapproachability between people [2] and decrease loneliness [3] but also moderate depression [4] and life stress [5]. Thus, it is important to have the elderly being supported through the internet and by the internet. Still, despite all the benefits, the elder people in any society are the sole group that exposed to the internet the least [6]. The main reason lies in the lack of information preparation, lack of manipulative ability, anxiety, and dehumanization of not accustomed to computers [7]. Further studies have found that most elderly people use the internet for telecommunication which plays an important role in their social functions [8]. Yet, some studies correspondingly have shown that there are still quite a few elderly people who refuse to use computers or those who give up halfway through their studies [9] due to frustration or anxiety.

Facing the era of the aging society, proper use of information technology and the internet can make up for the impact of interpersonal contacts decline and physical degradation. Technology has always been aimed at making people’s lives more convenient. Under the current wave of continuous innovation in information technology, especially, in the area of Artificial Intelligence, exploring the ways to meet the technological needs of the elderly, the elderly can use technology and information capabilities to support their own independent livings and social interactions and assist in managing and providing care. In turn, it promotes the social, mental and physical health of the elderly, improves their quality of life, and achieves the goal of successful, healthy and active aging.

Together, advances in Artificial Intelligence and information technology have changed the ways we live, and promise a bright future for aging human beings. Through a literature review, this article intends to integrate the goal of active aging and the advance of Artificial Intelligence and information technology in a state-of-the-art manner. It configures out a conceivable tactic for the elderly to live a happier and healthier life based on the infrastructure of ICT.

References

  1. World Health Organization (2002) Active Aging-A policy framework. http://whqlibdoc.who.int/hq/2002/WHO_NMH_NPH_02.8.pdf
  2. Bobillier Chaumon ME, Michel C, Tarpin Bernard F, Croisile B (2014) Can ICT improve the quality of life of elderly adults living in residential home care units? From actual impacts to hidden artefacts. Behaviour & Information Technology 33: 574-590.
  3. Cotten SR, Anderson WA, McCullough BM (2013) Impact of internet use on loneliness and contact with others among older adults: cross-sectional analysis. Journal of Medical Internet Research 15: 39. [crossref]
  4. Cotten SR, Ford G, Ford S, Hale TM (2012) Internet use and depression among older adults. Computers in Human Behavior 28: 496-499.
  5. Wright KB (2000) Social support satisfaction, on-line communication apprehension, and perceived life stress within computer-mediated support groups. Communication Research Reports 17: 139-147.
  6. Baker C (2013) A connection for all ages: Enabling the benefits of high-speed Internet access for older adults. AARP Public Policy Institute 79: 18.
  7. Cutler SJ, Hendricks J, Guyer A (2003) Age differences in home computer availability and use. The Journals of Gerontology Series B: Psychological Sciences and Social Sciences 58: 271-S280. [crossref]
  8. Hilt ML, Lipschultz JH (2004) Elderly Americans and the Internet: E-mail, TV news, information and entertainment websites. Educational Gerontology 30: 57-72.
  9. Namazi KH, McClintic M (2003) Computer use among elderly persons in long-term care facilities. Educational Gerontology 29: 535-550.

The Challenge of Integrated Care

DOI: 10.31038/IMROJ.2021625

Introduction

Serious and continuing illnesses have risen to prominence everywhere with generally increased life expectancy and somewhat fewer threats to health and life due to acute illness [1]. Health care systems that invest heavily in acute hospitals are recognising the need to repurpose services to include care beyond their walls to where people with prevalent chronic illnesses live. Multiple services – both medical and social and often low-tech – are required by patients with multiple morbidities, not the stock-in-trade of many major hospitals.

Now, the intention is to provide care for the patient as an individual rather than as a recipient of separate programs of care for his or her several separate medical problems (arthritis, heart disease and mild dementia). Anecdotes tell of four cars parked outside the home of a patient with multimorbidity, each bearing a therapist for one aspect of the patient’s problems. Chronic diseases such as those mentioned are the leading cause of death in Australia, with over 51% of hospitalisations and 89% of deaths associated with chronic disease [1]. They also cause a large out-of-pocket burden for many, with as many as 78% of Chronic Obstructive Pulmonary Disease (COPD) patients experiencing economic hardship while managing their illness [2]. Many chronic diseases are preventable [3], but despite this, preventative health makes up only 1.3% of all health spending [4], begging the question ‘Is it time we evaluated our current system?’.

‘Integrated care’ refers to the concern to improve the overall patient experience, from prevention to post-discharge care, and attain both greater value and efficiency from our health delivery model. It aims to address the fragmentation which often occurs in patient services; through integrated care the hope is that now the patient will benefit from a more holistic, joined-up service so that useless duplication and inappropriate admissions to hospital will be reduced.

In Australia, which enjoys high levels of health and generous financial investment in health care, much experimentation has occurred with different configurations of integrated care (as this joined-up pattern of hospital and community care is termed). In western Sydney, two programs (among many) conducted in recent years give insights into what can be done with modest investment and decisive management to improve the quality of life of patients with multiple chronic problems. The two small examples with which we are familiar, do not provide a clear set of directions about what to do in providing integrated care. Rather, because of our marginal involvement in them we been able to observe their operation and note what works well.

The Respiratory Ambulatory Care Service (RACS)

To assist patients with severe chronic obstructive lung disease (and usually other problems as well), this program was established by Professor John Wheatley, a respiratory physician at Westmead Hospital, ably assisted by Mary Roberts, a nurse practitioner, at Blacktown Hospital in 2001 with NSW Health Chronic and Complex Care funding. Over the years it was modified to meet the needs of the population [5]. The program had 8 pulmonary rehabilitation classes a day across Western Sydney Local Health District, with 12 patients enrolled in each class, with a text message support service which had over 100 patients enrolled in the Breathlessness Clinic. These patients were assessed at Blacktown Hospital by a physician, a physiotherapist, and a nurse.

Initially starting as a pure pulmonary rehabilitation program, it developed into a comprehensive COPD management program with a 24-hour helpline with COPD action plans [6]. A ten-week program of exercises and support was arranged for each patient. They were then cared for at home by the ambulatory team with regular visits by the nurses. A laptop-based medical record was maintained for each patient. The laptop passed to the duty nurse each night. Each patient was encouraged to contact the team by phone if they had a problem, and many did, especially at night when an attack of breathlessness might lead to panic which, without the support of the RACS, usually led to an ambulance call to take them to the hospital emergency department.

A conversation at 2 am with a nurse who knew the patient and had their electronic record in front of them on their laptop, could help decide if hospital admission (the default option in the absence of someone to speak to, with massive social dislocation to the patient and expense to the health service) is required or whether the patient can be ‘talked down’ and reassured to go back to bed, their problem to be fully explored, at home, in daylight. Past patients also had access to this 24-hour helpline which was utilised by patients who had not been in years, and a monthly subscription newsletter for education and information.

The program has been fully described in publications [6] SRL assisted for two years as a respiratory physician, servicing a clinic once a week and occasionally accompanying the nurses on home visits.

The program was established by Wheatley because he saw how patients once beyond the hospital could easily flounder for lack of specialised support. General practitioners often did not have the time or the access to resources available to the RACS team. By maintaining strong links between the specialists and the nurse led RACS team, integration was achieved. The results of the program were impressive with hospital admissions halved among program participants in the year after enrolment compared with the year before. Furthermore, during ongoing the COVID-19 pandemic, RACS was altered to provide telehealth and tele-education, as well as text messaging support. This not only is a great example of how such a system can evolve to suit the needs of the population, but a potential glimpse into the future.

Perhaps the most important caution is that health service managers should not be seduced into supporting integrated care programs because they believe they save money (they may) but rather should support them because they lead to a better quality of life for enrolled patients, albeit often at increased cost. It is misleading in the long-term to promise without evidence that ‘integrated care reduces hospital costs by keeping people out of hospital.’

Worldwide, the demand for hospital beds is such that if a bed is emptied because a chronically ill patient is cared for in the community instead, it is quickly filled by someone else (say, with a femoral neck fracture) and the costs to the health system remain unchanged. Clinicians know this and their interest in integrated care is because it is good medicine, not because it is cheap. In recruiting clinical staff to integrated care programs it is important to make this point strongly.

The Western Sydney Integrated Care Demonstrator Project

In 2016, the New South Wales (NSW) Ministry of Health provided affirmative funding to several health districts to support demonstration projects in integrated care. An allocation to the Western Sydney Local Health District enabled the development, again with a nurse manager and this time an extensive team of health professionals of different disciplinary skills and interests from both the hospital and the community, in relation to the care of patients with diabetes, heart disease and cardiovascular problems.

Although these three disease themes were developed relatively independently, they were linked through patient recruitment and documentation. Hospital specialists were critical to the development and implementation of the project as were local general practitioners. Nurses played a pivotal role in making the program happen, assisting greatly in the recruitment of patients both in Westmead Hospital and the western Sydney community through general practice.

This was a more complex program than RACS and required more managerial effort because of the number and diversity of practitioners involved and because the motivation for the program was ‘top down’, i.e., it came from NSW Health primarily rather than from practitioner concerns for better care of their patients. Practitioners needed education and support to be persuaded to participate.

The program used several strategies, including care facilitators, extensive use of IT, action plans for specialist care, shared care plans, the establishment of a rapid access and stabilisation service for patients that avoided them having to use the Emergency Department if they deteriorated, support payments to general practices to enrol and document the progress of enrolees, and promotion of the concept of a patient centred medical home.

Qualitative evaluation of the program was conducted, and the results are detailed in two papers by the principal evaluation research person [7,8]. SRL chaired the evaluation research advisory committee for the program.

Conclusion

There are several takeaway messages from these two programs. First, there is a big challenge in bringing the multiple players, both in the community and in the hospital, into a harmonious and productive team. This requires sensitivity and professional management. Effective integrated care relies on negotiation among several professional groups and separate government agencies, e.g., health and social services. Second, the recruitment of patients to these programs necessitates patient explanation and a responsiveness to questions that patients will have about their continuing care. People who are sick are frequently anxious not only about their health but also about the adequacy and dependability of their care. Familiarity with one or more carers, often a nurse, is important to achieve continued participation by patients and their carers.

Third, integrated care programs must be well organised and managed and this requires resources both in terms of workforce and money. The lines of responsibility (and accountability) are often long and intertwined and it is unusual for this arrangement to proceed smoothly in every respect. Negotiation is needed at many points in the program and once again time and patience are needed. The development of tailored IT arrangements to enable integrated care is critical and time-consuming.

Fourth – and there is a serious risk here – the program may be hijacked by managers who are ignorant of the detail of effective integrated care and see it as a way to save money. This is implausible [9] and can lead to program failure. Advocacy for the program is essential at all stages. In this regard it is very helpful to have leadership in the management of the program by senior and respected clinicians, both in the hospital and also in the community.

Fifth, the evaluation of integrated care programs is difficult because of the complexity of the relations among different groups of players. Comparison of patients managed conventionally and via integrated care is hard to engineer to the rigorous standards of a randomised controlled trial. The outcomes desired from integrated care often have to do with marginal improvement in quality of life. Even using an end-point such as reductions in hospital admissions can miss the point: some patients may need more rather than fewer admissions if the integrated care program brings to light problems that were previously not managed or not managed well.

In conclusion, the use of integrated care for the optimal management of patients with complex, serious, and continuing illness offers advantages especially for those living outside institutions and not in hospitals or care homes. An effective integrated care program should include aspects of an increased focus on preventative and population health, changes to the patients experience while admitted in hospitals, and higher levels of community support and care for patients outside of hospital walls [10]. Although in its early stages of development, it is attracting great interest among patients, their carers and families, and clinicians seeking to offer them the best quality of care.

References

  1. Australian Institute of Health and Welfare 2020. Australia’s health 2020: in brief. Australia’s health series no. 17 Cat. no. AUS 232. Canberra: AIHW.
  2. Essue B, Kelly P, Roberts M, Leeder S, Jan S (2011) We can’t afford my chronic illness! The out-of-pocket burden associated with managing chronic obstructive pulmonary disease in western Sydney, Australia. J Health Serv Res Policy 16: 226-231. [crossref]
  3. Australian Institute of Health and Welfare 2014 Australia’s health 2014. Australia’s health series no. 14. Cat. no. AUS 178. Canberra: AIHW.
  4. HJ, AS (2017) Preventive health: How much does Australia spend and is it enough? Canberra: Foundation for Alcohol Research and Education.
  5. Smith TA, Roberts MM, Cho J-G, Klimkeit E, Luckett T, et al. (2020) Protocol for a Single-Blind, Randomized, Parallel-Group Study of a Nonpharmacological Integrated Care Intervention to Reduce the Impact of Breathlessness in Patients with Chronic Obstructive Pulmonary Disease. Palliative Medicine Reports 1: 296-306.
  6. Roberts MM, Leeder SR, Robinson TD (2008) Nurse-led 24-h hotline for patients with chronic obstructive pulmonary disease reduces hospital use and is safe. Intern Med J 38: 334-340. [crossref]
  7. Trankle SA, Usherwood T, Abbott P, Roberts M, Crampton M, et al. (2019) Integrating health care in Australia: a qualitative evaluation. BMC Health Services Research 19: 954.
  8. Trankle SA, Usherwood T, Abbott P, Roberts M, Crampton M, et al. (2020) Key stakeholder experiences of an integrated healthcare pilot in Australia: a thematic analysis. BMC Health Services Research 20: 925. [crossref]
  9. Nolte E, Pitchforth E (2014) What is the evidence on the economic impacts of integrated care? Copenhagen Ø, Denmark: World Health Organisation.
  10. Baxter S, Johnson M, Chambers D, Sutton A, Goyder E, et al. (2018) The effects of integrated care: a systematic review of UK and international evidence. BMC Health Services Research 18: 350. [crossref]

Chemical Composition Similarity Relationships among the Various Organs of the Ilex cornuta Lindl. & Paxton Based on the Analysis of Hydrophilic Volatile Compounds

DOI: 10.31038/IMROJ.2021624

Abstract

In performing molecular profiling of secondary metabolites, a lot of research has focused on biogenic volatile organic compounds with medium to low polarity. In this study, chemical composition similarity relationships among the various organs of the Ilex cornuta Lindl. & Paxton were assessed based on the analysis of hydrophilic volatile compounds. GC-MS analysis was conducted to characterize and classify the chemical compounds. A total of 36, 46, 42, 25, 64, 26 compounds have been respectively extracted from the root, stem, stem skin, leaf, flower and fruit. The six organs have 3 common compounds and large percentages of exclusive compounds ranging from 36.0% to 62.5% with a mean of 49.8%, indicating substantial component differences among the different organs. The percentage of overlapping compounds between each of the two organs ranges from 10.9% to 44.0%, which is relatively small, further demonstrating the strong organ specificity of the chemical composition. The overlapping index is used to reveal the similarity among the organs. The stem shares the maximum similarity while the fruit the minimum similarity with the other organs. Aside from fruit, the average overlapping indices between each of the other two organs correlate well to their physical proximity. In conclusion, hydrophilic volatile metabolites are a class of natural products that are rarely investigated but constitute a significant part of the plant chemical composition. Chemical profiling of these metabolites could provide a valuable tool for the plant taxonomy and help understand the chemically mediated biological phenomena.

Keywords

Chemical composition similarity, GC-MS, Hydrophilic volatile compounds, Ilex cornuta Lindl. & Paxton, Plant taxonomy

Introduction

Plant taxonomy is traditionally conducted based on macroscopic and microscopic morphological characteristics. Growing evidence suggests that many biologically relevant entities could be missed in the studies that rely solely on morphological traits, particularly since speciation is not always accompanied by morphological change [1,2]. In recent years, plant chemical taxonomy has been developed to perform classification based on a wide array of biologically active secondary metabolites [3]. The expression of secondary metabolites could vary due to convergent evolution or differential gene expression [4], suggesting that the metabolite content of plants may reveal more information on the bioactive pattern of plants in comparison to morphology characterization [5].

In performing molecular profiling of secondary metabolites, a lot of research has focused on biogenic volatile organic compounds with medium to low polarity [6-9]. Volatile compounds are secreted and part of them are volatilized immediately after secretion [10,11]. The remaining part is stored in the special structure of the plant as in the case of essential oils [12-14]. Additionally, Berlinck and collaborators found that the vast majority of new compounds from natural sources reported in recent literature are compounds of medium to low polarity. Water-soluble, volatile, minor and photosensitive natural products are yet poorly known. One of the possible reasons for this trend could be that organic solvents of medium to low polarity used in isolation procedures require less time and less sophisticated instrumentation to be evaporated [15]. The author speculates that there is a class of hydrophilic volatile compounds in plants that are dispersed or dissolved in the water phase, evaporated with water vapor, and whose polarity and volatility are somewhere between essential oils and water-soluble compounds. To protect this type of ingredients from loss during extraction, water vapor distillation is used to collect volatile compounds that are dispersed or dissolved in the plant’s water phase. The root, stem, stem skin, leaf, flower and fruit of the Ilex cornuta Lindl. & Paxton were analyzed as study samples. Volatile essential oils were removed by using Soxhlet extraction method. Hydrophilic volatile compounds obtained by water reflux extraction are characterized and classified by quantitative GC-MS. The study revealed the potential use of hydrophilic volatile metabolites in the plant taxonomy and understanding the chemically mediated biological phenomena.

Materials and Methods

Material

Ilex cornuta Lindl. & Paxton was collected in Nanjing, China. Its roots, stems, stem skins, leaves, flowers and fruits were washed, cut into pieces, dried at 30°C and stored at 2-8°C prior to use.

Chemicals and Reagents

Ethyl acetate was purchased from Xilong Chemical Co., Ltd (Shantou, China). Hexane was purchased from Shanghai Titan Scientific Co., Ltd (Shanghai, China). Activated carbon was purchased from Shanghai Chemical Reagent Procurement Center (Shanghai, China). C7-C40 saturated alkanes standard was purchased from Anpel Laboratory Technologies Inc. (Shanghai, China).

Sample Preparation

Each sample was sliced and dried at 30°C. After ground into powder, the samples were sieved through 80 mesh followed by 180 mesh. Approximately 6 g of the sample were subjected to Soxhlet extractor method with hexane for 24 hrs to remove essential oils and other lipophilic compounds. The remainder was then removed and dried at 30°C in the ventilation cabinet. Approximately 4 g of the dried powder was then added into a 6 x 7 cm nonwoven bag together with three glass balls of 4 cm diameter. At least 3 segments of thread were used to separate and tighten the bag into 3 parts, each containing a glass ball and even amount of the dried powder. The bag was then placed in a flask and 2100 mL of water was subsequently added to soak the powder for about 2 hrs. After reflux extraction for 6 hrs, 2 L of distilled water was collected. The same reflux extraction was repeated to collect another 1 L of distilled water for a total of 3 L. After cooling, activated carbon (4 g) was added to absorb the active ingredients from the 3 L of distilled water for about 8 hrs. The activated carbon containing the active ingredients was then filtered and dried at 30°C for 12 hrs. Ethyl acetate was subsequently added to isolate the active ingredients from the activated carbon using Soxhlet extractor method for 8 hrs. The resulting ethyl acetate extract was left in the ventilation cabinet to dry at 30°C. The dried active ingredients were finally re-dissolved using ethyl acetate, filtrated through 0.22 µm filter and analyzed using GC-MS.

GC-MS Analysis

Analysis of hydrophilic volatile compounds was performed using Shimadzu GCMS-QP2010 Single Quadrupole GC-MS (Kyoto, Japan). A Rxi-1 ms GC capillary column (30 cm length, 0.25 mm inner diameter and 0.25 µm thick film) from Shimadzu (Kyoto, Japan) was used for analysis.

One microliter of sample was injected in split mode with split ratio of 5 to 1. GC inlet temperature is set at 280°C. High purity nitrogen (≥99.999%) was used as carrier gas in constant flow mode at 1 mL/min. The initial temperature of the GC oven is set at 60°C and held for 1 min, then ramped at 4°C/min to 160°C and held for 3 mins, followed by 2°C/min to 280°C and held for 6 mins. Finally, the temperature is raised to 300°C at 4°C/min and held for 6 mins. The mass spectrometer was operated in positive electron ionization mode at 70 eV and all spectra were recorded in full scan with a mass range of 40-700 Da. The interface temperature is set at 280°C and ion source temperature is set at 250°C.

Data Processing and Compound Identification

The GC-MS data processing was done with Shimazdzu GCMS Solution software. Compound identification was performed by applying several assignments, e.g., reference standard analysis, retention index calculation, and by NIST08 Spectrum Library comparison. Only peaks with area greater than 3 million are analyzed. The overlapping percentage is calculated by the number of overlapping compounds divided by the total number of hydrophilic volatile compounds from each of the two organ and times 100. Overlapping index is calculated by the number of overlapping compounds squared and divided by the total number of hydrophilic volatile compounds from each of the two organs. In addition, hierarchical clustering analysis was performed with Python to assess the similarities between each of the two organs by analyzing the number of overlapping hydrophilic volatile compounds.

Results and Discussion

The root, stem, stem skin, leaf, flower and fruit of the Ilex cornuta Lindl. & Paxton contain compounds that are water soluble and can volatilize with water vapor. These hydrophilic compounds do not separate from the water phase and possess greater polarity than essential oils. The largest number (64) of hydrophilic volatile compounds are isolated from the flower and the smallest (25) from the leaf, indicating that the number of hydrophilic volatile compounds varies greatly from organ to organ. The hydrophilic volatile compounds include aromatics, fatty acids, furans, heterocycle, esters, alkanes, ketones, halogens and other types of small molecular compounds. This is a diverse group of molecules that could contribute to the expression of biological information about the plant. Tables 1-6 present the lists of hydrophilic volatile compounds identified from the root, stem, stem skin, leaf, flower and fruit, respectively. The bold and italic fonts in the table are used to refer to exclusive compounds that are only found in the specific organ and not contained in any other organ.

Table 1: List of the hydrophilic volatile compounds identified from the root of the Ilex cornuta Lindl. & Paxton.

No RT RI Compound Formula
1 8.434 1041 2(3H)-Furanone, dihydro-4-hydroxy- C4H6O3
2 8.555 1044 2-Oxo-n-valeric acid C5H8O3
3 8.623 1047 2,3-Anhydro-d-galactosan C6H8O4
4 9.159 1064 Acetic acid, hexyl ester C8H16O2
5 9.767 1084 2-Cyclopenten-1-one, 3-ethyl-2-hydroxy- C7H10O2
6 12.753 1173 Octanoic Acid C8H16O2
7 13.662 1199 2-Furancarboxaldehyde,5-(hydroxymethyl)- C6H6O3
8 16.053 1269 Nonanoic acid C9H18O2
9 19.301 1364 Benzaldehyde, 4-(methylthio)- C8H8OS
10 23.459 1492 1H-2-Benzopyran-1-one, 3,4-dihydro-8-hydroxy-3-methyl- C10H10O3
11 23.660 1498 3-Acetoxydodecane C14H28O2
12 25.161 1546 7-Hydroxy-3-(1,1-dimethylprop-2-enyl) coumarin C14H14O3
13 25.496 1557 Dodecanoic acid C12H24O2
14 25.696 1564 Estra-1,3,5(10)-trien-17. beta. – ol C18H24O
15 26.109 1577 Butyric acid, 3-tridecyl ester C17H34O2
16 26.829 1600 Hexadecane C16H34
17 27.305 1613 Ethanone, 1-[2-(5-hydroxy-1,1-dimethylhexyl)-3-methyl-2-cyclopropen-1-yl]- C14H24O2
18 28.020 1631 Thieno[3,2-c]pyridin-4(5H)-one C7H5NOS
19 28.671 1649 Dodecanoic acid, 3-hydroxy- C12H24O3
20 30.636 1700 2-Bromotetradecane C14H29Br
21 32.780 1750 7-Methyl-Z-tetradecen-1-ol acetate C17H32O2
22 35.860 1821 1,2-Benzenedicarboxylic acid, bis(2-methylpropyl) ester C16H22O4
23 37.894 1867 2a-isopropyl-9,10a-dimethyl-6-methylenedodecahydro-1H-cyclopenta[4′,5′]cycloocta[1′,2′:1,5]cyclopenta[1,2-b]oxiren-4-ol C20H32O2
24 39.903 1912 1,2-Benzenedicarboxylic acid, butyl octyl ester C20H30O4
25 41.687 1951 n-Hexadecanoic acid C16H32O2
26 49.181 2119 7-Hexadecenal, (Z)- C16H30O
27 50.098 2139 9-Octadecenamide, (Z)- C18H35NO
28 50.483 2148 Octadecanoic acid C18H36O2
29 59.601 2362 2-Methyloctadecan-7,8-diol C19H40O2
30 65.148 2499 1,2-Benzenedicarboxylic acid, diisooctyl ester C24H38O4
31 73.761 2726 13-Docosenamide, (Z)- C22H43NO
32 77.825 2840 3-Phenyl-2-ethoxypropylphthalimide C19H19NO3
33 83.874 3017 9,10-Secocholesta-5,7,10(19)-triene-3,24,25-triol, (3.beta.,5Z,7E)- C27H44O3
34 89.708 3197 Heptanoic acid, docosyl ester C29H58O2
35 92.123 3265 Isophthalic acid, allyl pentadecyl ester C26H40O4
36 102.267 3561 Benzenepropanoic acid, 3,5-bis(1,1-dimethylethyl)-4-hydroxy-, octadecyl ester C35H62O3

Note: The bold and italic fonts are used to refer to exclusive compounds. RT: Retention time. RI: Reflex index.

Table 2: List of the hydrophilic volatile compounds identified from the stem of the Ilex cornuta Lindl. & Paxton.

No RT RI Compound Molecular
1 13.608 1198 2-Furancarboxaldehyde, 5-(hydroxymethyl)- C6H6O3
2 19.258 1363 4-Hydroxy-2-methoxybenaldehyde C8H8O3
3 21.565 1433 Cyclopentanemethanol,.alpha.-(1-methylethyl)-2-nitro-, [1.alpha.(S*),2.alpha.]- C9H17NO3
4 23.85 1504 4,8-Decadienal, 5,9-dimethyl- C12H20O
5 24.743 1533 Megastigmatrienone C13H18O
6 25.469 1556 Dodecanoic acid C12H24O2
7 25.681 1563 1-Cyclohexene-1-methanol, .alpha.,2,6,6-tetramethyl- C11H20O
8 26.105 1577 Pentanoic acid, 2,2,4-trimethyl-3-carboxyisopropyl, isobutyl ester C16H30O4
9 26.245 1581 Phenol, 3,4,5-trimethoxy- C9H12O4
10 26.495 1589 2-Methyl-4-(2,6,6-trimethylcyclohex-1-enyl)-but-2-en-1-ol C14H24O
11 27.127 1608 Benzaldehyde, 4-hydroxy-3,5-dimethoxy- C9H10O4
12 27.37 1614 Ethanone, 1-[2-(5-hydroxy-1,1-dimethylhexyl)-3-methyl-2-cyclopropen-1-yl]- C14H24O2
13 27.88 1628 Thieno[3,2-c]-pyridin-4(5H)-one C7H5NOS
14 28.27 1638 Spiro-[4.5]-decan-7-one, 1,8-dimethyl-8,9-epoxy-4-isopropyl- C15H24O2
15 28.685 1649 2-Bromo dodecane C12H25Br
16 29.172 1662 Ethanol, 2-(octadecyloxy)- C20H42O2
17 29.971 1683 1-(2-Hydroxy-4,5-dimethoxy-phenyl)-ethanone C10H12O4
18 30.271 1691 2-Propenal, 3-(4-hydroxy-3-methoxyphenyl)- C10H10O3
19 30.399 1694 Butanol, 1-[2,2,3,3-tetramethyl-1-(3-methyl-1-penynyl)-cyclopropyl]- C17H30O
20 30.641 1700 Heptadecane C17H36
21 31.037 1710 Hexadecane, 2,6,10,14-tetramethyl- C20H42
22 31.345 1717 4a-Dichloromethyl-4,4a,5,6,7,8-hexahydro-3H-naphthalen-2-one C11H14Cl2O
23 31.75 1726 Adamantane, 1-thiocyanatomethyl- C12H17NS
24 32.052 1733 9-(3,3-Dimethyloxiran-2-yl)-2,7-dimethylnona-2,6-dien-1-ol C15H26O2
25 32.512 1744 1-Decanol, 2-hexyl- C16H34O
26 32.788 1750 Cyclopropane, 1-(1-hydroxy-1-heptyl)-2-methylene-3-pentyl- C16H30O
27 33.683 1771 3-Isobutyryl-6-isopropyl-2,3-dihydropyran-2,4-dione C12H16O4
28 34.92 1800 Heneicosane C21H44
29 35.489 1813 Heptadecane, 2,6,10,15-tetramethyl- C21H44
30 35.86 1821 1,2-Benzenedicarboxylic acid, bis(2-methylpropyl) ester C16H22O4
31 37.316 1854 1-Hexadecanol C16H34O
32 37.898 1867 2a-isopropyl-9,10a-dimethyl-6-methylenedodecahydro-1H-cyclopenta[4′,5′]-cycloocta[1′,2′:1,5]-cyclopenta-[1,2-b]oxiren-4-ol C20H32O2
33 39.907 1912 1,2-Benzenedicarboxylic acid, butyl 8-methylnonyl ester C22H34O4
34 41.693 1951 n-Hexadecanoic acid C16H32O2
35 43.899 2000 Eicosane C20H42
36 49.179 2119 12-Methyl-E,E-2,13-octadecadien-1-ol C19H36O
37 50.464 2148 Octadecanoic acid C18H36O2
38 59.603 2362 2-Methyloctadecan-7,8-diol C19H40O2
39 65.152 2499 1,2-Benzenedicarboxylic acid, diisooctyl ester C24H38O4
40 73.757 2726 13-Docosenamide, (Z)- C22H43NO
41 83.861 3016 Ethyl iso-allocholate C26H44O5
42 89.711 3197 Heptanoic acid, docosyl ester C29H58O2
43 92.16 3266 Isophthalic acid, allyl pentadecyl ester C26H40O4
44 92.66 3280 17-(1,5-Dimethylhexyl)-10,13-dimethyl-3-styrylhexadecahydrocyclopenta[a]phenanthren-2-one C35H52O
45 94.571 3331 4-Norlanosta-17(20),24-diene-11,16-diol-21-oic acid, 3-oxo-16,21-lactone C29H42O4
46 102.263 3561 Benzenepropanoic acid, 3,5-bis(1,1-dimethylethyl)-4-hydroxy-, octadecyl ester C35H62O3

Note: The bold and italic fonts are used to refer to exclusive compounds. RT: Retention time. RI: Reflex index.

Table 3: List of the hydrophilic volatile component identified from the stem skin of the Ilex cornuta Lindl. & Paxton.

No RT RI Compound Molecular
1 12.765 1173 Octanoic Acid C8H16O2
2 13.818 1204 2-Furancarboxaldehyde, 5-(hydroxymethyl)- C6H6O3
3 19.283 1364 Benzaldehyde, 3-hydroxy-4-methoxy- C8H8O3
4 21.526 1432 2H-Pyran-2-one, 5,6-dihydro-6-pentyl- C10H16O2
5 23.372 1489 4,6-di-tert-Butyl-m-cresol C15H24O
6 23.599 1496 12-Oxa-[tetracyclo[5.2.1.1(2,6).1(8,11)]]dodecan-10-ol, 3-acetoxy- C13H18O4
7 23.856 1504 2,6-Dimethoxybenzoquinone C8H8O4
8 25.171 1547 1H-Benzocyclohepten-7-ol, 2,3,4,4a,5,6,7,8-octahydro-1,1,4a,7-tetramethyl-, cis- C15H26O
9 25.317 1551 2(5H)-Furanone, 4-methyl-5,5-bis(2-methyl-2-propenyl)- C13H18O2
10 25.462 1556 Dodecanoic acid C12H24O2
11 25.694 1564 2-Oxabicyclo[3.3.0]oct-7-en-3-one, 7-(1-hydroxypentyl)- C12H18O3
12 25.922 1571 Dodecane, 2,6,10-trimethyl- C15H32
13 26.114 1577 Pentanoic acid, 2,2,4-trimethyl-3-carboxyisopropyl, isobutyl ester C16H30O4
14 26.335 1584 3-Butyl-4-nitro-pent-4-enoic acid, methyl ester C10H17NO4
15 26.514 1590 2-Dodecen-1-yl(-)succinic anhydride C16H26O3
16 26.838 1600 Heptadecane C17H36
17 27.227 1611 Benzaldehyde, 4-hydroxy-3,5-dimethoxy- C9H10O4
18 27.929 1629 2,6,10,10-Tetramethyl-1-oxaspiro-[4.5]decan-6-ol C13H24O2
19 28.288 1638 4-Isobenzofuranol, octahydro-3a,7a-dimethyl-, (3a.alpha.,4.beta.,7a.alpha.)-(.+-.)- C10H18O2
20 29.187 1662 Ethanol, 2-(hexadecyloxy)- C18H38O2
21 29.827 1679 2-Cyclohexen-1-one, 3-(3-hydroxybutyl)-2,4,4-trimethyl- C13H22O2
22 29.956 1682 Cyclopentanone, 2-(1-adamantyl)- C15H22O
23 30.308 1692 alpha. Isomethyl ionone C14H22O
24 30.649 1700 2-Bromotetradecane C14H29Br
25 31.047 1710 Hexadecane, 2,6,10,14-tetramethyl- C20H42
26 31.774 1727 Adamantane, 1-thiocyanatomethyl- C12H17NS
27 32.083 1734 E,E-6,8-Tridecadien-2-ol, acetate C15H26O2
28 32.522 1744 1-Decanol, 2-hexyl- C16H34O
29 32.801 1751 7-Methyl-Z-tetradecen-1-ol acetate C17H32O2
30 33.682 1771 7-Bromo-3a,6,6-trimethyl-hexahydro-benzofuran-2(3H)-one C11H17BrO2
31 35.475 1813 Heptadecane, 2,6,10,15-tetramethyl- C21H44
32 35.876 1822 1,2-Benzenedicarboxylic acid, bis(2-methylpropyl) ester C16H22O4
33 37.903 1867 Dodecane, 1,2-dibromo- C12H24Br2
34 39.916 1912 Dibutyl phthalate C16H22O4
35 41.653 1951 n-Hexadecanoic acid C16H32O2
36 65.178 2500 1,2-Benzenedicarboxylic acid, diisooctyl ester C24H38O4
37 73.760 2726 13-Docosenamide, (Z)- C22H43NO
38 93.411 3301 1,2-Benzenedicarboxylic acid, diundecyl ester C30H50O4
39 93.650 3307 Isophthalic acid, allyl pentadecyl ester C26H40O4
40 100.522 3505 9-Octadecenoic acid (Z)-, phenylmethyl ester C25H40O2
41 101.150 3525 2,6-Lutidine 3,5-dichloro-4-dodecylthio- C19H31Cl2NS
42 102.301 3562 Benzenepropanoic acid, 3,5-bis(1,1-dimethylethyl)-4-hydroxy-, octadecyl ester C35H62O3

Note: The bold and italic fonts are used to refer to exclusive compounds. RT: Retention time. RI: Reflex index.

Table 4: List of the hydrophilic volatile component of the leaf of the Ilex cornuta Lindl. & Paxton.

No RT RI Compound Molecular
1 13.543 1196 2-Furancarboxaldehyde, 5-(hydroxymethyl)- C6H6O3
2 14.110 1212 2-Furancarboxaldehyde, 6-(hydroxymethyl)- C6H6O4
3 14.318 1218 2-Furancarboxaldehyde, 7-(hydroxymethyl)- C6H6O5
4 25.089 1544 Bicyclo[3.2.0]heptan-6-one, 2-acetyl-3,3-dimethyl-7-(1-methylethyl)- C14H22O2
5 25.453 1556 Dodecanoic acid C12H24O2
6 25.692 1564 trans-Z-.alpha.-Bisabolene epoxide C15H24O
7 26.117 1577 4,6,10,10-Tetramethyl-5-oxatricyclo[4.4.0.0(1,4)]dec-2-en-7-ol C13H20O2
8 26.493 1589 7-Heptadecene, 1-chloro- C17H33Cl
9 26.831 1600 Hexadecane C16H34
10 28.088 1633 3-Pyridinecarboxylic acid, 1,6-dihydro-4-hydroxy-2-methyl-6-oxo-, ethyl ester C9H11NO4
11 30.644 1700 Heptadecane C17H36
12 31.038 1710 Hexadecane, 2,6,11,15-tetramethyl- C20H42
13 32.440 1742 2-Cyclohexen-1-one, 4-hydroxy-3,5,6-trimethyl-4-(3-oxo-1-butenyl)- C13H18O3
14 32.801 1751 7-Methyl-Z-tetradecen-1-ol acetate C17H32O2
15 34.479 1790 Pentadecyl trifluoroacetate C17H31F3O2
16 34.925 1800 Heptadecane, 2,6,10,15-tetramethyl- C21H44
17 35.476 1813 Nonadecane C19H40
18 35.872 1822 1,2-Benzenedicarboxylic acid, bis(2-methylpropyl) ester C16H22O4
19 41.601 1949 n-Hexadecanoic acid C16H32O2
20 43.458 1991 1-Nonadecene C19H38
21 59.608 2362 2-Methyloctadecan-7,8-diol C19H40O2
22 73.760 2726 13-Docosenamide, (Z)- C22H43NO
23 92.239 3268 Isophthalic acid, allyl pentadecyl ester C26H40O4
24 93.235 3296 1,2-Benzenedicarboxylic acid, 2-butoxyethyl butyl ester C18H26O5
25 94.006 3317 Phthalic acid, propyl octadecyl ester C29H48O4

Note: The bold and italic fonts are used to refer to exclusive compounds. RT: Retention time. RI: Reflex index.

Table 5: List of the hydrophilic volatile component identified from the flower of the Ilex cornuta Lindl. & Paxton.

No RT RI Compound Molecular
1 9.359 1070 2,2-Dimethyl-3-vinyl-bicyclo[2.2.1]heptane C11H18
2 9.987 1091 Cyclohex-3-enecarboxaldehyde, 2,4,6-trimethyl-, oxime C10H17NO
3 12.197 1156 Phenol, 3-ethyl- C8H10O
4 12.649 1170 Benzoic acid C7H6O2
5 12.797 1174 Glucosamine, N-acetyl-N-benzoyl- C15H19NO7
6 13.333 1190 Benzothiazole C7H5NS
7 15.613 1256 Phenol, 2,3,5-trimethyl- C9H12O
8 16.214 1273 5H-Inden-5-one, 1,2,3,6,7,7a-hexahydro- C9H12O
9 16.640 1286 Hydroquinone C6H6O2
10 17.145 1300 Cyclohexanol, 1-methyl-4-(1-methylethylidene)- C10H18O
11 17.280 1304 Cyclohexanol, 2-methyl-5-(1-methylethenyl)-, (1.alpha.,2.beta.,5.alpha.)- C10H18O
12 17.772 1319 2,7-Octadiene-1,6-diol, 2,6-dimethyl- C10H18O2
13 18.160 1330 trans-Z-.alpha.-Bisabolene epoxide C15H24O
14 18.430 1338 (3S,4R,5R,6R)-4,5-Bis(hydroxymethyl)-3,6-dimethylcyclohexene C10H18O2
15 19.298 1364 4-Hydroxy-2-methoxybenaldehyde C8H8O3
16 19.508 1370 2-Cyclopenten-1-one, 4-hydroxy-3-methyl-2-(2-propenyl)- C9H12O2
17 21.040 1417 Phenol, 2-pentyl- C11H16O
18 21.311 1425 2-Propen-1-ol, 2-methyl-3-(2,6,6-trimethyl-2-cyclohexen-1-yl)-, (E)- C13H22O
19 21.602 1434 3-(2-Hydroxy-cyclopentylidene)-2-methyl-propionic acid C9H14O3
20 21.838 1442 5-​Benzofuranacetic acid, 6-​ethenyl-​2,​4,​5,​6,​7,​7a-​hexahydro-​3,​6-​dimethyl-​α-​methylene-​2-​oxo-​, methyl ester C16H20O4
21 23.259 1486 8-Methylenecyclooctene-3,4-diol C9H14O2
22 23.514 1494 1-(3,6,6-Trimethyl-1,6,7,7a-tetrahydrocyclopenta[c]pyran-1-yl)ethanone C13H18O2
23 24.011 1509 1-Acetamido-1,2-dihydro-2-oxopyridine C7H8N2O2
24 24.675 1531 cis-Z-.alpha.-Bisabolene epoxide C15H24O
25 24.767 1534 Cyclopentan-1-al, 4-isopropylidene-2-methyl- C10H16O
26 25.085 1544 Ethanone, 1-(1a,2,3,5,6a,6b-hexahydro-3,3,6a-trimethyloxireno[g]benzofuran-5-yl)- C13H18O3
27 25.514 1558 Dodecanoic acid C12H24O2
28 25.685 1563 Bicyclo[3.3.1]nonan-9-one, 1,2,4-trimethyl-3-nitro-, (2-endo,3-exo,4-exo)-(.+-.)- C12H19NO3
29 25.899 1570 2-Cyclohexen-1-one, 3-(3-hydroxybutyl)-2,4,4-trimethyl- C13H22O2
30 26.127 1578 Ledol C15H26O
31 26.498 1590 1-Hexadecanol C16H34O
32 26.840 1600 Hexadecane C16H34
33 27.155 1609 Spiro[androst-5-ene-17,1′-cyclobutan]-2′-one, 3-hydroxy-, (3.beta.,17.beta.)- C22H32O2
34 27.486 1617 Bicyclo[3.1.0]hexane-6-methanol, 2-hydroxy-1,4,4-trimethyl- C10H18O2
35 28.099 1634 3-Pyridinecarboxylic acid, 1,6-dihydro-4-hydroxy-2-methyl-6-oxo-, ethyl ester C9H11NO4
36 28.615 1647 Bromoacetic acid, dodecyl ester C14H27BrO2
37 28.684 1649 Chloroacetic acid, 4-tetradecyl ester C16H31ClO2
38 29.178 1662 2-Dodecen-1-yl(-)succinic anhydride C16H26O3
39 29.777 1678 2-Hydroxy-1,1,10-trimethyl-6,9-epidioxydecalin C13H22O3
40 29.951 1682 1-Cyclopropene-1-pentanol, .alpha.,.epsilon.,.epsilon.,2-tetramethyl-3-(1-methylethenyl)- C15H26O
41 30.651 1701 2-Bromotetradecane C14H29Br
42 31.045 1710 Tetradecane, 1-chloro- C14H29Cl
43 31.355 1717 5.beta.,7.beta.H,10.alpha.-Eudesm-11-en-1.alpha.-ol C15H26O
44 31.582 1722 7-Hexadecenal, (Z)- C16H30O
45 31.771 1727 Pentane-2,4-dione, 3-(1-adamantyl)- C15H22O2
46 32.092 1734 Butanol, 1-[2,2,3,3-tetramethyl-1-(3-methyl-1-penynyl)-cyclopropyl]- C17H30O
47 32.468 1743 Pyrrolo[1,2-a]pyrazine-1,4-dione, hexahydro-3-(2-methylpropyl)- C11H18N2O2
48 32.769 1750 Tetradecanoic acid C14H28O2
49 33.645 1771 1-Decanol, 2-hexyl- C16H34O
50 34.485 1790 Pentadecyl trifluoroacetate C17H31F3O2
51 34.932 1801 Heptadecane, 2,6,10,15-tetramethyl- C21H44
52 35.479 1813 1-Octanol, 2-butyl- C12H26O
53 35.873 1822 1,2-Benzenedicarboxylic acid, bis(2-methylpropyl) ester C16H22O4
54 36.928 1845 5,10-Diethoxy-2,3,7,8-tetrahydro-1H,6H-dipyrrolo[1,2-a;1′,2′-d]pyrazine C14H22N2O2
55 37.910 1867 2-Hexadecene, 3,7,11,15-tetramethyl-, [R-[R*,R*-(E)]]- C20H40
56 39.389 1900 Nonadecane C19H40
57 41.675 1951 n-Hexadecanoic acid C16H32O2
58 43.480 1991 1-Nonadecene C19H38
59 46.996 2069 3-Chloropropionic acid, heptadecyl ester C20H39ClO2
60 48.984 2114 9,12-Octadecadienoic acid (Z,Z)- C18H32O2
61 49.228 2120 9-Octadecenal, (Z)- C18H34O
62 50.660 2152 Ethyl iso-allocholate C26H44O5
63 52.394 2192 9-Tricosene, (Z)- C23H46
64 73.770 2727 13-Docosenamide, (Z)- C22H43NO

Note: The bold and italic fonts are used to refer to exclusive compounds. RT: Retention time. RI: Reflex index.

Table 6: List of the hydrophilic volatile component identified from the fruit of the Ilex cornuta Lindl. & Paxton.

No RT RI Compound Molecular
1 9.133 1063 Mequinol C7H8O2
2 9.303 1069 Phenol, 4-methyl- C7H8O
3 9.430 1073 Hexane, 3-bromo- C6H13Br
4 9.923 1089 Phenylethyl Alcohol C8H10O
5 10.510 1107 4-Acetylbutyric acid C6H10O3
6 12.643 1169 Benzoic acid C7H6O2
7 13.559 1196 2-Furancarboxaldehyde, 5-(hydroxymethyl)- C6H6O3
8 15.378 1249 1,5-Cyclooctadien-4-one C8H10O
9 17.652 1315 Phenol, 2,6-dimethoxy- C8H10O3
10 19.180 1361 Benzaldehyde, 3-hydroxy-4-methoxy- C8H8O3
11 21.852 1442 2-Ethoxyphenylacetonitrile C10H11NO
12 22.103 1450 Benzeneacetonitrile, 4-hydroxy- C8H7NO
13 22.466 1461 Coumarin, 8-methyl- C10H8O2
14 25.187 1547 1,4-Benzenediol, 2-(1,1-dimethylethyl)- C10H14O2
15 25.508 1558 Dodecanoic acid C12H24O2
16 25.876 1569 3,5-Octadienoic acid, 7-hydroxy-2-methyl-, [R*,R*-(E,E)]- C9H14O3
17 25.938 1571 2-Cyclopenten-1-one, 4-hydroxy-3-methyl-2-(2-propenyl)- C9H12O2
18 26.125 1577 1b,5,5,6a-Tetramethyl-octahydro-1-oxa-cyclopropa[a]inden-6-one C13H20O2
19 26.492 1589 4-Chloro-3-n-hexyltetrahydropyran C11H21ClO
20 27.323 1613 Ethanone, 1-[2-(5-hydroxy-1,1-dimethylhexyl)-3-methyl-2-cyclopropen-1-yl]- C14H24O2
21 30.643 1700 Heptadecane C17H36
22 32.760 1750 Tetradecanoic acid C14H28O2
23 35.878 1822 1,2-Benzenedicarboxylic acid, bis(2-methylpropyl) ester C16H22O4
24 41.694 1952 n-Hexadecanoic acid C16H32O2
25 48.863 2111 9,12-Octadecadienoic acid, methyl ester C19H34O2
26 49.244 2120 9-Octadecenal, (Z)- C18H34O

Note: The bold and italic fonts are used to refer to exclusive compounds. RT: Retention time. RI: Reflex index.

As shown in Table 7, the total number of hydrophilic volatile compounds isolated from the six organs ranges from 25 to 64. There are 3 common compounds in the six organs, i.e. Dodecanoic acid, 1,2-Benzenedicarboxylic acid, bis(2-methylpropyl) ester and n-Hexadecanoic acid. This accounts for 12.0% of total hydrophilic volatile compounds for the leaf and 4.7% for the flower with an average of 8.4% for all the six organs, indicating the little commonality of the six organs. Each organ also has its exclusive compounds which are not found in any other organ. The percentage of exclusive compounds follows the order of flower > fruit > stem skin > root > stem > leaf. The flower has the largest number and percentage of the exclusive compounds, 40 and 62.5%, respectively. The leaf has the smallest number and percentage of the exclusive compounds, 9 and 36.0%, respectively. The stem and stem skin display medium numbers of exclusive compounds. The average percentage of the exclusive compounds in the six organs was 49.8%, nearly half, indicating strong organ specificity. These results provide evidence to support the practice of the traditional herbal medicine to treat the diseases using either the whole plant or part of the plants depending on which part contains the substances that can be used for therapeutic purposes.

Table 7: The number and percentage of the common and exclusive hydrophilic volatile compounds identified from the six organs.

Organ Root Stem Stem Skin Leaf Flower Fruit
Total Compounds 36 46 42 25 64 26
Common Compounds 3
Percentage of Common Compounds 8.3% 6.5% 7.1% 12.0% 4.7% 11.5%
Exclusive Compounds 17 21 21 9 40 15
Percentage of Exclusive Compounds 47.2% 45.7% 50.0% 36.0% 62.5% 57.7%

Table 8 presents the number of overlapping compounds, overlapping percentage and overlapping index. The stem and stem skin share the largest number (15) of overlapping compounds. The overlapping percentage is calculated to be 32.6% for the stem and 35.7% for the stem skin. The smallest number (5) of overlapping compounds are found between root and fruit, leaf and fruit. The percentage of overlapping compounds between each of the two organs ranges from 10.9% to 44.0%, which is relatively small, further demonstrating substantial component differences among the different organs. The overlapping index is used to reveal the similarity among the organs. Two organs share the same number of overlapping compounds, but the overlapping index could be different if the total number of the hydrophilic volatile compounds differs. The more total number of the hydrophilic volatile compounds, the less the percentage of the overlapping compounds and smaller the overlapping index. That is why the average overlapping indices between the two organs is introduced to normalize the difference. In addition, total average overlapping indices is derived to calculate the mean of the average overlapping indices between each organ and the other five organs. Based on Table 8, the total average overlapping indices for each organ follows the order of stem > stem skin > root > leaf > flower > fruit. The total average overlapping indices for the stem is the greatest at 3.056, indicating the stem share the maximum similarity with the plant. The total average overlapping indices for the fruit was the smallest at 1.090, indicating that the fruit share the minimum similarity with the plant. And there is not much difference in the average overlapping indices between fruit and the other five organs. Except fruit, the average overlapping indices between each of the two organs correlate well to their physical proximity. The root, stem and stem skin are the organs that the plant survive and grow, and their total average overlapping indices are greater than 2.5. The overlapping index differences among these three organs are small, and they share the most in common. As an evergreen plant, the leaf is symbiotically related to the plant although the relationship between each leaf and the plant is cyclical, so the leaf is secondarily related to the plant. The flower and fruit are also cyclically related to the plant and have the most distant relationship. The leaf, flower and fruit are necessary but not survival organs for the growth of the plant. The relationship between the organs and the plant generated from the analysis of the hydrophilic volatile compounds is consistent with their biological function.

Table 8: The number of overlapping compounds, overlapping percentage and overlapping index.

Organ1 Organ 2 Number of overlapping compounds Overlapping percentage Overlapping index for Organ 1 Overlapping index for Organ 2 Average overlapping indices between organ 1 and 2 Total average overlapping Indices
Root Stem 14 38.9% 5.444 4.261 4.853

2.522

Stem skin 11 30.6% 3.361 2.881 3.121
Leaf 9 25.0% 2.250 3.240 2.745
Flower 7 19.4% 1.361 0.766 1.064
Fruit 5 13.9% 0.694 0.962 0.828
Stem Root 14 30.4% 4.261 5.444 4.853

3.056

Stem skin 15 32.6% 4.891 5.357 5.124
Leaf 9 19.6% 1.761 3.240 2.501
Flower 10 21.7% 2.174 1.266 1.720
Fruit 6 13.0% 0.783 1.385 1.084
Stem skin Root 11 26.2% 2.881 3.361 3.121 2.710
Stem 15 35.7% 5.357 4.891 5.124
Leaf 9 21.4% 1.929 3.240 2.585
Flower 10 21.4% 1.929 1.266 1.598
Fruit 6 14.3% 0.857 1.385 1.121
Leaf Root 9 36.0% 3.240 2.250 2.745

2.435

Stem 9 36.0% 3.240 1.761 2.501
Stem skin 9 36.0% 3.240 1.929 2.585
Flower 11 44.0% 4.840 1.891 3.366
Fruit 5 20.0% 1.000 0.962 0.981
Flower Root 7 10.9% 0.766 1.361 1.064

1.844

Stem 10 15.6% 1.563 2.174 1.859
Stem skin 10 14.1% 1.266 1.929 1.598
Leaf 11 17.2% 1.891 4.840 3.366
Fruit 7 10.9% 0.766 1.885 1.326
Fruit Root 5 19.2% 0.962 0.694 0.828

1.090

Stem 6 23.1% 1.385 1.000 1.193
Stem skin 6 23.1% 1.385 0.857 1.121
Leaf 5 19.2% 0.962 1.000 0.981
Flower 7 26.9% 1.885 0.766 1.326

Conclusion

The root, stem, stem skin, leaf, flower and fruit of the Ilex cornuta Lindl. & Paxton contain hydrophilic volatile compounds that are evenly distributed in the water phase of the various organs of the plant and can volatilize with water vapor. The number and type of hydrophilic volatile compounds vary from organ to organ. There is only a small number of common compounds among the six organs and the number of overlapping compounds between each of the two organs is also relatively small. In addition, there are large number of exclusive compounds from each organ. Therefore, it is possible to identify the plant through the assessment of the hydrophilic volatile compounds isolated from each individual organ.

In conclusion, we found that hydrophilic volatile metabolites are a class of natural products that are rarely investigated but constitute a significant part of the plant chemical composition. Chemical profiling of these secondary metabolites could provide a valuable tool for identification and authentication of the plant samples, as well as resolving taxonomic problems and understanding the chemically mediated biological phenomena.

References

  1. Bickford D, Lohman DJ, Sodhi NS, Ng PKL, Meier R, et al. (2007) Cryptic species as a window on diversity and conservation. Trends Ecol Evol 22: 148-155. [crossref]
  2. Heinrichs J, Kreier HP, Feldberg K, Schmidt AR, Zhu RL, et al. (2011) Formalizing morphologically cryptic biological entities: New insights from DNA taxonomy, hybridization, and biogeography in the leafy liverwort Porella platyphylla (Jungermanniopsida, Porellales). Am J Bot 98: 1252-1262. [crossref]
  3. Ludwiczuk A (2014) Fingerprinting of secondary metabolites of liverworts: chemosystematic approach. J of AOAC Int 97: 1234-1243.
  4. Wink M (2003) Evolution of secondary metabolites from an ecological and molecular phylogenetic perspective. Phytochemistry 64: 3-19. [crossref]
  5. Liu K, Abdullah AA, Huang M, Nishioka T, Altaf-Ul-Amin M, et al. (2017) Novel Approach to Classify Plants Based on Metabolite-Content Similarity. BioMed Res Int. doi: 10.1155/2017/5296729
  6. Ghaste M, Narduzzi L, Carlin S, Vrhovsek U, Shulaev V, et al. (2015) Chemical Composition of Volatile Aroma Metabolites and Their Glycosylated Precursors that Can Uniquely Differentiate Individual Grape Cultivars. Food Chem 188: 309-319. [crossref]
  7. Peters K, Treutler H, Doll S, Kindt ASD, Hankemeier T, et al. (2019) Chemical Diversity and Classification of Secondary Metabolites in Nine Bryophyte Species. Metabolites 9: 222. [crossref]
  8. Staszek D, Orlowska M, Rzepa J, Wrobel MS, Kowalska T (2014) Fingerprinting of the Volatile Fraction from Selected Thyme Species by Means of Headspace Gas Chromatography with Mass Spectrometric Detection. J of AOAC Int 97: 1250-1258. [crossref]
  9. Tundis R, Peruzzi L, Menichini F (2014) Phytochemical and biological studies of Stachy Species in Relation to Chemotaxonomy: A Review. Phytochemistry 102: 7-39. [crossref]
  10. Peñuelas J, Llusià J (1999) Seasonal emission of monoterpenes by the Mediterranean tree Quercus ilex in field conditions: Relations with photosynthetic rates, temperature and volatility. Physiol Plant 105: 641-647.
  11. Llusia J, Penuelas J (2000) Seasonal patterns of terpene content and emission from seven mediterranean woody species in field conditions. Am J Bot 87: 133-140. [crossref]
  12. Ormeo E, Goldstein A, Niinemets ü (2011) Extracting and trapping biogenic volatile organic compounds stored in plant species. TRAC-Trend Anal Chem 30: 978-989.
  13. Claudia G, Roberta A, Daniela L, Giacomo T, Laura S, et al. (2018) Salvia verticillata: Linking glandular trichomes, volatiles and pollinators. Phytochemistry 155: 53-60.
  14. Wei X, Song M, Chen C, Tong H, Liang G, et al. (2018) Juice volatile composition differences between Valencia orange and its mutant Rohde Red Valencia are associated with carotenoid profile differences. Food Chem 245: 223-232. [crossref]
  15. Berlinck RGS, Monteiro AF, Bertonha AF, Bernardi DI, Gubiani JR, et al. (2019) Approaches for the isolation and identification of hydrophilic, light-sensitive, volatile and minor natural products. Nat Prod Rep 36: 981-1004. [crossref]

Mechanisms of Anti-Melanogenic and Proliferative Effects of Colla Corii Asini (E’jiao)

DOI: 10.31038/IMROJ.2021623

Abstract

Natural compounds have been reported for the development of cosmetic skin care products but it remains a challenge to find safe and useful ones. Colla corii asini (E’jiao), or donkey-hide gelatin (DHG) prepared by concentrating stewed Equus asinus L. donkey hide, has been useful in traditional Chinese medicine. However, its anti-melanogenic and skin care effects have not been explored. In this study, the biological effect of DHG was tested on murine B16-F10 melanocytes and human HaCaT keratinocytes. The cell signal pathway mechanisms by DHG were also examined by western blot assay. The results showed that DHG was not cytotoxic to cells and had an anti-melanogenic effect by inhibiting tyrosinase activity and reducing melanin contents in B16-F10 melanocytes. It also showed an anti-oxidative effect of reducing ROS generation in H2O2-stressed HaCaT keratinocytes. DHG dose-dependently enhanced phosphorylation of ERK, but reduced p-JNK and p-p38 proteins in B16-F10 cells under the UV stress. This is consistent with the results of other anti-melanogenic agents. Therefore, this suggested DHG had a potential for skin whitening and skin care applications.

Keywords

Anti-melanogenesis, Donkey-hide gelatin, E’jiao, Proliferation, UV stress

Introduction

Medicinal products have been used for centuries to promote healthy skin. Skin care products have gained a competitive market not only for clinical applications but also for esthetical purpose. Despite the widespread use of natural ingredients, the discovery of biologically active compounds, the development of these substances into new cosmetic products remain an important challenge [1]. Skin pigmentation is caused by melanins, which are synthesized by melanocytes [2]. Tyrosinase is an enzyme that catalyzes two rate-limiting reactions in melanogenesis including hydroxylation of L-tyrosine into L-3,4-dihydroxyphenylalanine (L-DOPA) and further oxidation of L-DOPA into dopaquinone, while highly reactive dopaquinone can spontaneously polymerize to form melanin [3]. Many tyrosinase inhibitors from natural or synthetic sources have been reported to include polyphenols, benzaldehyde and benzoate derivatives, long-chain lipids and steroids, other natural or synthetic inhibitors, and irreversible inhibitors [4]. However, few tyrosinase inhibitors are applied in cosmetic and medicinal fields for skin-lightening due to their toxicity or potential hazards [5]. Therefore it is necessary to search a natural anti-melanogenic agent without significant side effects.

Colla corii asini (E’jiao), donkey-hide gelatin (DHG) prepared by concentrating stewed Equus asinus L. donkey hide, is a traditional Chinese medicinal ingredient. It has been used in China for antianemic therapy for over 2,000 years [6,7]. The chemical constituents of Colla corii asini include amino acids, proteins/gelatins, polysaccharides, volatile substances, and inorganic substances. It has been reported as having anti-aging, antitumor, immunomodulatory, anti-inflammatory effects [8,9]. However, its potential for skin care or skin whitening has not been explored.

In this study, the antimelanogenic effect of DHG was evaluated in murine B16-F10 melanoma cells and the antioxidative effect in human HaCaT keratinocytes. Because the extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathways have been shown to negatively regulate melanogenesis in melanocytes and melanoma cells [10,11], we also investigated the effect of DHG on these signaling pathways. The beneficial mechanisms of DHG on these cells were examined for its potential application on the skin care.

Materials and Methods

Chemicals

Donkey hide gelatin (Colla corii asini, DHG or e-jiao) was purchased from Dong-E-E-Jiao Co., Ltd. (Dong’E, Shangdon, China). Mushroom tyrosinase (3320 units/mg), 3,4-dihydroxy-L-phenylalanin (L-dopa), sodium hydroxide (NaOH) and other reagents were obtained from Sigma-Aldrich (St. Louis, MO, USA). Murine melanoma cell-line, B16-F10 (BCRC60031) and human keratinocytes HaCaT cell-line were gifts of Dr. Chih-Cheng Lin and originally obtained from the Bioresource Collection and Research Center (BCRC, Hsinchu, Taiwan). Fetal bovine serum (FBS), penicillin/streptomycin (P/S), and Dulbecco’s modified Eagle’s medium (DMEM) were purchased form Hyclone (Logan, UT, USA). A TD-3D skin analyzer with whole spectrum, cross-polarized, and UV lighting was used to record and measure surface and subsurface skin conditions. The analyzer was obtained from Hofonchu Corp (New Taipei, Taiwan).

Cell Culture and Viability Assay

The B16-F10 cells and HaCaT keratinocytes were cultured in DMEM medium with 10% FBS, 50 mg/ml P/S at 37°C with a 5% CO2 incubator. The B16-F10 cells or HaCaT cells were seeded in 24-well plates at a density of 5 × 105 cells/well. DHG extract was prepared with either double distilled (RO) water or ethanol (1 g/10 ml). After 24 h of incubation, the culture medium was replaced with fresh culture medium containing various concentrations of DHG and further incubated for another 24 h. The cell viability was determined by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. The culture was washed with phosphate buffered saline (PBS) and replaced with MTT solution, and then incubated at 37°C for 1 h. The formazan formed by dimethyl sulfoxide (DMSO) solubilized cells was determined at an absorbance of 540 nm using an ELISA reader (Molecular Devices, Sunnyvale, CA, USA).

Skin Analysis

DHG was grinded with normal saline (1 g/9 ml) for 5 min and centrifuged at 3000 g for 10 min. One ml of the supernatant was added to the filter paper (9 × 9 cm2). The filters containing either DHG or RO water were then laid on a volunteer’s left and right cheek, respectively, for 15 min. After rinsing with RO water, gently dry cheek with lens paper, waiting for 5 min, and the volunteer’s facial skin was assessed with a TD-3D skin analyzer. Stain, wrinkles, and skin texture were analyzed for the effects of DHG. Since tyrosinase is a significant key in melanogenesis, tyrosinase inhibition is a common method to avoid melanin biosynthesis. The effect of DHG on tyrosinase activity of B16-F10 cells was determined [12]. The cells were seeded at 1~3 × 105 with 10 ml DMEM complete medium (10% FBS, 50 mg/ml P/S) in 24-well plates and treated with various concentrations of DHG for 48 h. The cells were then harvested by using a lysis buffer (0.1 M PBS, pH 6.8, containing 1% Triton X-100 and protease inhibitor). Cells were then disrupted by repeatedly freezing and thawing five times. Cell lysates were centrifuged at 14,000 g for 15 min. The protein concentration in the supernatant from cell lysate was determined by using Bradford assay (Bio-Rad, Richmond, CA, USA) and normalized. After pre-heated to 37°C, an aliquot of 50 μl of each samples was transferred into a well of the 96-well plate and reacted with 50 μl of 1 mg/ml L-DOPA at 37°C for 1 h. Tyrosinase activity was then determined by measurement of the absorbance at 475 nm dynamically within 30 min. The molar absorbance coefficient 3700 (mol/l·cm)-1 was used to calculate tyrosinase activity. Tyrosinase activity unit was defined as the amount of enzyme required to oxidize 1 µM min-1of the substrate (L-DOPA) under standard assay conditions. The inhibition rate of tyrosinase activity (%) = (A-B) / A × 100%.

A: Absorbance of the non-treated sample, B: Absorbance of the DHG-treated sample

Measurement of Melanin Content

B16-F10 cells were seeded at a density of 5 × 105 cells/ml in the 24-well culture plates and incubated at 37°C with 5% CO2 for 24 h. The B16-F10 cells were treated with various concentrations of DHG for 24 h under 100 mJ of UV exposure. After washed with PBS, the culture was centrifuged for 30 min at 12000 g, and treated with 100 μl of 1 N NaOH solution for 30 min at 60°C. For the melanin content, an aliquot of 80 μl of culture medium was transferred to a microplate and determined at an absorbance of 405 nm with a melanin standard curve [13].

Measurement of Reactive Oxygen Species (ROS)

ROS was determined with H2DCF-DA [10]. This nonfluorescent compound accumulates within cells upon deacetylation. H2DCF then reacts with ROS to form fluorescent dichlorofluorescein (DCF). HaCaT cells were plated in 96-well plates and grown for 24 h before the addition of DMEM plus 10 μM H2DCF-DA and various concentrations of DHG, incubation for 1 h at 37°C, and treatment with 800 μM H2O2 for 60 or 120 min. Cells were then washed twice with room temperature Hank’s balanced salt solution (HBSS without phenol red). Cellular fluorescence was monitored on a Fluoroskan Ascent fluorometer (Labsystems Oy, Helsinki, Finland) using an excitation wavelength of 485 nm and emission wavelength of 538 nm. The inhibition of ROS was calculated as the previous formula.

Western Blot Assay

B16-F10 cells and HaCaT cells were plated in 24-well plates and grown for 24 h. Then both types of cells were incubated with various concentration of DHG for 1 h at 37°C, but only B16-F10 cells were under UV (100 mJ) stress. Extracted protein samples from each treatment group (containing 50 μg of protein) were separated on 12% sodium dodecyl sulfate-polyacrylamide gels and transferred to immobile polyvinylidene difluoride membranes (Millipore, Billerica, MA). The membranes were incubated for 1 h with 5% dry skim milk in TBST buffer (0.1M Tris-HCl, pH 7.4, 0.9% NaCl, 0.1% Tween-20) to block non-specific binding. Then, they were incubated with rabbit antibodies against AKT, p-JNK, p-ERK, p-p38 (Abcam, Cambridge, UK), and anti-β-actin (Jackson, West Grove, PA, USA). Subsequently, the membranes were incubated with the conjugated affinity goat anti-rabbit IgG (Jackson). Expression of these proteins was detected by a chemiluminescence detection system according to the manufacturer’s instructions (ECL, Amersham, Berkshire, UK) [10].

Results

Effect of DHG on Cell Viability

The effect of DHG on cell viability of human keratinocyte HaCaT cells and murine B16-F10 cells was evaluated. Cells treated with various concentrations were examined for cell viability by MTT assay. As shown in Figure 1, DHG from water extract did not exhibit a cytotoxic effect. Instead, it demonstrated a proliferative effect on HaCaT cells at concentrations of 0.5~1.0 mg/ml. Likewise, DHG at these ranges did not exhibit a cytotoxic effect on B16-F10 cells.

fig 1a

fig 1b

Figure 1: Effect of DHG on the cell viability by MTT assay. Human keratinocyte HaCaT cells or murine B16-F10 melanocytes were treated with various concentrations of DHG for 24 h and examined for cell viability. Each value is the mean + SE from three experiments. *p < 0.05 as compared with the HaCaT control (A), or UVB-treated control of B16-F10 cells (B).

Effect of DHG on Skin Test

A brief treatment of DHG showed a skin care effect. Skin analysis showed that the facial skin texture, pores, wrinkles, and red spots were significantly improved in ten healthy volunteers after DHG treatment (Table 1).

Table 1: Effect of DHG treatment on facial skin analysis.

Items

Control (Water)

DHG (0.1 g/ml)

Texture

37 ± 5

26 ± 3*

Pore

25 ± 4

17 ± 3*

Wrinkles

14 ± 3

 8 ± 3*

Erythema

40 ± 7

25 ± 7*

Glossy

48 ± 11

49 ± 9

Color

20 ± 6

19 ± 6

Skin tone

20 ± 5

41 ± 7

Stain

54 ± 11

55 ± 13

Effect of DHG on Tyrosinase Activity

The DHG-treated B16-F10 cells under 100 mJ of UVB exposure were compared for tyrosinase activity. The results showed that both extracts of DHG (at 1 mg/ml) inhibited tyrosinase activities of 10.7 to 14.1% as compared to that of the UVB group (Figure 2).

fig 2

Figure 2: Inhibition of tyrosinase activity by DHG treatment. Tyrosinase activity of B16-F10 cells was compared for the treatment with and without DHG for 48 h. Each value is the mean + SE from three experiments. *p < 0.05 as compared with the UVB-treated control of B16-F10 cells.

Effect of DHG on Melanin Content of B16–F10 Cells

To further evaluate the potential of DHG as an anti-melanogenic agent, the melanin content from DHG-treated B16-F10 cells under 100 mJ of UVB exposure was determined. At 24 h post-treatment, the melanin content measured an absorbance at 405 nm. The result showed that water extract of DHG (1 mg/ml) had a melanin inhibitory activity of 16.4% (Figure 3).

fig 3

Figure 3: Inhibition of the melanin generation by DHG treatment. The melanin content of B16-F10 cells was assessed for 24 h treatment with and without DHG. Each value is the mean + SE from three experiments. *p < 0.05 as compared with the UVB-treated control.

Effect of DHG on ROS Generation

Since DHG had a skin care effect on texture, pores, and wrinkles, it was necessary to examine its effect on the cells under oxidative stress. Therefore HaCaT cells pretreated with10 μM H2DCF-DA and DHG were under H2O2 stress for 60 or 120 min. Cellular fluorescence was monitored for ROS generation. As we expected, the result showed that ROS was dose-dependently reduced by treatments of water extract of DHG (from 0.5 to 1 mg/ml) (Figure 4).

fig 4

Figure 4: Effect of DHG on ROS generation. HaCaT cells pretreated with H2DCF-DA and DHG were exposed to H2O2 for 60 min. Each ROS value is the mean + SE from three experiments. *p < 0.05 as compared with the H2O2-treated control.

Effect of DHG on Cell Signaling Pathways

The cells were treated with various concentration of DHG for 1 h at 37°C, but B16-F10 cells were treated under UVB (100 mJ) stress. The results showed that DHG enhanced the phosphorylation of ERK significantly, but moderately on JNK, ERK, and p38 proteins in HaCaT cells. Interestingly, DHG dose-dependently enhanced phosphorylation of ERK, but reduced p-JNK and p-p38 proteins in B16-F10 cells under the UV stress (Figure 5).

fig 5a

fig 5b

Figure 5: Effect of DHG on cell signaling pathways. HaCaT cells were treated DHG and B16-F10 cells were treated with DHG and under UVB (100 mJ) stress for 1 h at 37°C. Representative data of AKT, phosphorylation of JNK, ERK, and p38 proteins are shown in HaCaT cells (A) and B16-F10 cells (B).

Discussion

The results show that DHG has no cytotoxic effect on the cell viability of HaCaT keratinocytes and B16-F10 melanoma cells. This is consistent with the use donkey hide in traditional Chinese medicine, which has been used for over 2,000 years for its unique therapies. The results showed that DHG has an anti-melanogenic effect by inhibiting tyrosinase activity and reducing melanin contents in B16-F10 melanocytes. These results suggest that DHG from donkey hide can be a potential candidate for development as an anti-pigmenting agent. Interestingly, DHG dose-dependently enhanced the proliferation of HaCaT keratinocytes and B16-F10 melanocytes. It has been reported that keratinocytes from the epidermis participates wound repair in the skin [14,15]. Keratinocytes contribute to melanocyte activity by influencing their microenvironment, partly through the secretion of endothelin-1 proteins [16]. In addition, DHG reduced H2O2-induced ROS generation significantly. Since there is a close relationship between oxidative stress and ageing [17], these results suggest that DHG together with other compounds [12,18,19], might help to preserve a healthy epidermis and dermis and prevent the visible signs of skin aging. This was also demonstrated by a short-term treatment of DHG on healthy volunteers’ facial skin textures, pores, wrinkles, and red spots.

One of the key amino acids of Colla corii asini is glycine [20]. Two human major collagen peptides, prolyl-hydroxyproline (Pro-Hyp) and hydroxyprolyl-glycine (Hyp-Gly enhance cell proliferation. In addition, Pro-Hyp enhances the production of hyaluronic acid by dermal fibroblasts [16]. Glycine functions as a building block in the production of proteins. Glycine is a non-essential amino acid, which means it can be synthesized within the human body, therefore cosmetics and skin care products, glycine primarily functions as an anti-ageing ingredient based on its ability to improve moisture retention, increase collagen production, and promote skin repair and regeneration. Other bioactive compounds from Colla corii asini may also contribute its anti-aging, antitumor, immunomodulatory, anti-inflammatory and anti-anemic effects [21,22].

Melanogenesis in melanocytes is regulated by a very complex system [6]. ERK and PI3K/Akt signaling pathways have been shown to negatively regulate melanogenesis in melanocytes and melanoma cells [3,23]. Our results show that DHG dose-dependently enhanced phosphorylation of ERK, but reduced p-JNK and p-p38 proteins in B16-F10 cells under the UV stress. This is in agreement with a report that ceramide inhibits melanogenesis by activation of ERK and inhibition of ERK and Akt causes an increase in pigmentation in human melanocytes [12]. Similarly, imidazole derivative and thaginin A can inhibit tyrosinase and activate the ERK pathway [19,24-26].

Conclusion

In summary, DHG was not cytotoxic to cells and had an anti-melanogenic effect by inhibiting tyrosinase activity and reducing melanin contents in B16-F10 melanocytes. It also showed an antioxidative effect of reducing ROS generation in H2O2-stressed HaCaT keratinocytes. DHG dose-dependently enhanced phosphorylation of ERK, but reduced p-JNK and p-p38 proteins in B16-F10 cells under the UV stress. These beneficial mechanisms suggest its potential application in skin care.

Acknowledgement

The authors wish to thank the Testing and Analysis Center at Yuanpei University of Medical Technology (Hsinchu, Taiwan) for the HPLC analysis.

References

  1. Ando H, Kondoh H, Ichihashi M, Hearing VJ (2007) Approaches to identify inhibitors of melanin biosynthesis via the quality control of tyrosinase. Journal Investigative Dermatology 127: 751-761. [crossref]
  2. Birch-Machin MA, Bowman A (2016) Oxidative stress and ageing. British Journal of Dermatology 2: 26-29. [crossref]
  3. Chan CF, Lai ST, Guo YC, Chen MJ (2014) Inhibitory effects of novel synthetic methimazole derivatives on mushroom tyrosinaseand melanogenesis. Bioorganic & Medicinal Chemistry 22: 2809-2815.
  4. Chang TS (2009) An updated review of tyrosinase inhibitors. International Journal of Molecular Science 10: 2440-2475. [crossref]
  5. Claudinot S, Nicolas M, Oshima H, Rochat A, Barrandon Y (2005) Long-term renewal of hair follicles from clonogenic multipotent stem cells. Proceedings of the National Academy of Sciences of the United States of America 102: 14677-14682.
  6. Costin GE, Hearing VJ (2007) Human skin pigmentation: melanocytes modulate skin color in response to stress. The FASEB J 21: 976-994. [crossref]
  7. Dorni AC, Amalraj A, Gopi S, Varma K, Anjana SN (2017) Novel cosmeceuticals from plants – an industry guided review. Journal of Applied Research on Medicinal and Aromatic Plants 7: 1-26.
  8. Hameury S, Borderie L, Monneuse JM, Skorski G, Pradines D (2019) Prediction of skin anti-aging clinical benefits of an association of ingredients from marine and maritime origins: Ex vivo evaluation using a label-free quantitative proteomic and customized data processing approach. Journal of Cosmetic Dermatology 18: 355-370. [crossref]
  9. Hou CW, Chen YL, Chuang SH, Wang JS, Jeng KC (2014) Protective effect of a sesamin derivative, 3-bis (3-methoxybenzyl) butane-1, 4-diol on ischemic and hypoxic neuronal injury. Journal of Biomedical Science 21: 15. [crossref]
  10. Huang CC, Hsu BY, Wu NL, Tsui WH, Lin TJ, et al. (2010) Anti-photoaging effects of soy isoflavone extract (aglycone and acetylglucoside form) from soybean cake. International Journal of Molecular Science 11: 4782-4795. [crossref]
  11. Kim DS, Kim SY, Chung JH, Kim KH, Eun HC, et al. (2002) Delayed ERK activation by ceramide reduces melanin synthesis in human melanocytes. Cellular Signalling 14: 779-785. [crossref]
  12. Peng LH, Liu S, Xu SY, Chen L, Shan YH, et al. (2013) Inhibitory effects of salidroside and paeonol on tyrosinase activity and melaninsynthesis in mouse B16F10 melanoma cells and ultraviolet B-induced pigmentation in guinea pig skin. Phytomedicine 20: 1082-1087. [crossref]
  13. Huang JH, Huang CC, Fang JY, Yang C, Chan CM, et al. (2010) Protective effects of myricetin against ultraviolet-B-induced damage in human keratinocytes. Toxicology In Vitro 24: 21-28. [crossref]
  14. Hyter S, Coleman DJ, Ganguli-Indra G, Merrill GF, Ma S, et al. (2013) Endothelin-1 is a transcriptional target of p53 in epidermal keratinocytes and regulates ultraviolet-induced melanocyte homeostasis. Pigment Cell & Melanoma Research 26: 247-258. [crossref]
  15. Inoue N, Sugihara F, Wang X (2016) Ingestion of bioactive collagen hydrolysates enhance facial skin moisture and elasticity and reduce facial ageing signs in a randomised double-blind placebo-controlled clinical study. Journal of the Science of Food and Agriculture 96: 4077-4081. [crossref]
  16. Ito M, Liu Y, Yang Z, Nguyen J, Liang F, et al. (2005) Stem cells in the hair follicle bulge contribute to wound repair but not to homeostasis of the epidermis. Nature Medicine 11: 1351-1354. [crossref]
  17. Kim DS, Lee HK, Park SH, Chae CH, Park KC (2009) AVS-1357 inhibits melanogenesis via prolonged ERK activation. Die Pharmazie 64: 532-537. [crossref]
  18. Wang D, Ru W, Xu Y, Zhang J, He X, et al. (2014) Chemical constituents and bioactivities of Colla corii asini. Drug Discoveries & Therapeutics 8: 201-207. [crossref]
  19. Shen L, Chen H, Zhu Q, Wang Y, Wang S, et al. (2016) Identification of bioactive ingredients with immuno-enhancement and anti-oxidative effects from Fufang-Ejiao-Syrup by LC–MS(n) combined with bioassays. Journal of Pharmaceutical and Biomedical Analysis 117: 363-371. [crossref]
  20. Wu H, Ren C, Yang F, et al. (2016) Extraction and identification of collagen-derived peptides with hematopoietic activity from Colla Corii Asini. Journal of Ethnopharmacology 182: 129-136.
  21. Oka M, Nagai H, Ando H, et al. (2000) Regulation of melanogenesis through phosphatidylinositol 3-kinase-Akt pathway in human G361 melanoma cells. Journal of Investigative Dermatology 115: 699-703.
  22. Kim JH, Baek SH, Kim DH, Choi TY, Yoon TJ, et al. (2008) Downregulation of melanin synthesis by haginin A and its application to in vivo lightening model. Journal of Investigative Dermatology 128: 1227-1235.
  23. Lee SY, Baek N, Nam T-g (2016) Natural, semisynthetic and synthetic tyrosinase inhibitors. Journal Enzyme Inhibition and Medicinal Chemistry 31: 1-13. [crossref]
  24. Lv P, Zhao YJ, Qi F, Zhou XS, You JH, et al. (2011) Authentication of equine DNA from highly processed donkey-hide glue (Colla corii asini) using sine element. Journal of Food and Drug Analysis 19: 123-130.
  25. Wang D, Liu M, Cao J, Cheng Y, Zhuo C, et al. (2012) Effect of Colla corii asini (E’jiao) on D-galactose induced aging mice. Biological and Pharmaceutical Bulletin 35: 2128-2132. [crossref]
  26. Wu HZ, Yang F, Cui SY, Qin YF, Liu JW, et al. (2007) Hematopoietic effect of fractions from the enzyme digested colla corii asini on mice with 5-fluorouracil induced anemia. The American Journal of Chinese Medicine 35: 853-866. [crossref]

Chemical Characterization and Anti-Microbial Evaluation of the Eastern Nigerian Specie of African Mistletoe (Loranthus micranthus) Sourced From Citrus sinensis

DOI: 10.31038/IMROJ.2021622

Abstract

This present study is aimed at determining phytochemical constituents with the aid of GCMS technique and in vitro screening of crude methanol extract of the leaves of Loranthus micranthus Linn parasitic on Citrus sinensis tree sourced from Nsukka, in the eastern part of Nigeria for their antimicrobial activity against six human pathogens. Preliminary phytochemical screening was carried out on the crude extract. The results of the phytochemical analysis showed positive for tannins, flavonoids, steroids, alkaloids, triterpenes/sterols, glycosides and saponins. GCMS analysis revealed nine bioactive compounds in the crude methanol extract of Loranthus micranthus, which includes; Benzoic acid, 3,4,5-trimethoxy-, trimethylsilyl ester, 1,3,5-Triazine, 2,4,6-tris[(trimethylsilyl)oxy]-, Gallic acid, Beta-Amyrin, Beta-Sitosterol, Lup-20(29)-en-3-one. The crude methanol extract of Loranthus micranthus was subsequently partitioned into four solvents to obtain n-hexane, chloroform, ethyl acetate and methanol fractions respectively. The crude extract and the four fractions were observed for antimicrobial activities on the following pathogens; Escherichia coli, Pseudomonas aeruginosa, Bacillus subtilis, Aspergillums niger, Staphylocoocus aureus and Candida albicans at various concentrations using agar diffusion method. The results of the antimicrobial activity proved the ability of the crude methanol extract and the obtained fractions of Loranthus micranthus to inhibit these pathogens. Different bacterial species and fungi exhibited different sensitivities with variable extent towards the extract/fractions. The order of activity against selected bacteria was Candida albicans> Bacillus subtilis> Staphylococcus aureus> Escherichia coli. Only the crude methanol extract at a concentration of 25 mg/ml inhibited Pseudomonas aeruginosa. While Aspergillums niger was resistant to both the extract and fractions. The n-hexane and the methanol fractions of Loranthus micranthus exerted maximum antimicrobial activity against Candida albicans with an MIC of 1.25 and 0.625 mg/ml respectively. An indication that the plant possesses very potent antifungal activities The MIC for Bacillus subtilis was 1.25 for n-hexane and methanol fractions respectively. There is good evidence that the plant is more active against gram positive bacteria.

Keywords

Antimicrobial, Gas chromatography-Mass spectrometry analysis, Loranthus micranthus Linn, Phytochemical

Introduction

Citrus sinensis belongs to the Rutaceae family, commonly known as sweet orange, which is a much sought after fruit worldwide with immense cultural and historical significance. The fruit’s origin dates back to its mention in the Chinese literature of 314 BC [1]. Orange trees thrive in both tropical and subtropical climates, making the plant; one of the most cultivated globally [2]. In the last decade, sweet orange accounted for 70% of the citrus fruits cultivated [2]. Currently, the production of oranges has hit 73 million tonnes, with Brazil, China and India leading in the production of oranges [3]. The fruit is a major source of vitamin C, which led to the massive cultivation of oranges along trade routes of European sailors in the discovery age. There has been numerous reports on the bioactivities of sweet oranges by many scholars. The anti-oxidant activities have received immense attention; similarly, the antimicrobial activities of the essential oil, the juice and the peels have equally been documented. However, the bioactivity of the mistletoes parasitic on oranges has very scanty reports, owing to the obvious fact that orange tree rarely bear host to parasitic plants such as mistletoe. A literature search revealed that the anti-microbial activities of Loranthus micranthus from Citrus sinensis has not been carried out, despite the plethoral of anti-microbial activities attributed to Citrus sinensis. While the mistletoes of many host trees such as Pentaclethra macrophylla, Persea americana, Kola nitida, Kola acuminata and Hevea brasiliensis have been investigated and shown to possess numerous activities, which includes: antioxidant, antimicrobial, antidiarrhoeal, immunomodulatory, antidiabetic, antihypertensive, and hypolipidemic activities [4]. The Citrus sinensis mistletoe has not been investigated.

In my previous work, it was observed that mistletoes parasitic on the host trees with significant bioactivity possessed some of the reported activities of their host trees. While the mistletoes parasitic on the host trees with few significant bioactivities also showed less significant bioactivities [5]. In this current work, the chemical characterization and antimicrobial evaluation of Loranthus micranthus (LM) parasitic on Citrus sinensis is reported.

Materials and Methods

Plant Material

Fresh leaves of LM parasitic on Citrus sinensis were obtained in Oba in Nsukka LGA of Enugu State. The plant was identified by a botanist in the Department of Botany, University of Nigeria, Nsukka, after which a voucher specimen was deposited in the department.

Extraction Procedure

The LM leaves were dried at room temperature under a shade, and pulverized. Weighed quantities of the LM were extracted with aqueous methanol using soxhlet extractor. The obtained methanol extract was subsequently partitioned into the following four solvents: N-hexane, Chloroform, Ethyl acetate and Methanol sequentially.

Preliminary Screening

The phytochemical constituents of the methanol extracts were determined according to the method prescribed by Trease and Evans [6].

GC-MS Analysis of the Crude Extracts

The gas chromatography mass spectrometry (GC-MS) analysis of the crude methanol extract of the leaves of Loranthus micranthus parasitic on C. sinensis was quantitatively determined using an Agilent 7890B GC system coupled with an Agilent 5977A MSD with a Zebron-5MS column (ZB-5MS 30 m × 0.25 mm × 0.025 μm) (5%-phenylmethylpolysiloxane). The GC-grade helium served as the carrier gas at a constant flow rate of 2 mL/min. The crude extract was dissolved with ethanol and filtered before use. The column temperature was maintained at 60°C and gradually increased at 10°C per minute until a final temperature of 300°C was reached. The time taken for the GC-MS analysis was 30 min. The compounds were identified based on computer matching of the mass spectra with the NIST 11 MS library (National Institute of Standards and Technology library).

Materials for Anti-microbial Assay

Equipment: Microscope, autoclave, incubator, wire loop, Bunsen burner, markers, petri dish test tubes and McCartney bottle.

Reagents

Nutrient agar and broth, Sabourand’s dextrose agar and broth, dimethyl sulfoxide (DMSO), sterile distilled water.

Test Organisms

All organisms used were clinical isolates obtained from the laboratory of pharmaceutical microbiology, University of Port Harcourt. The research utilized two gram positive bacteria, two gram negative bacteria and two fungi. The organisms were; Escherichia coli, Pseudomonas aeruginosa, Bacillus subtilis, Aspergillums niger, Staphylocoocus aureus and Candida albicans. The organisms were sub cultured and standardized before use.

Anti-Microbial Assay Method

Agar diffusion by cup plate method was adopted as described [7]. The entire agar used was prepared according to the manufacturer’s specification. The glass wares were thoroughly washed and sterilized, suspensions of the test organisms were made and 0.05 ml of 0.5 McFarland standard of the test organism concentration were dispensed each in the plate and 20 ml of the sterile molten agar each were added, mixed and allowed to set/gel, using two fold serial dilution. Different concentration of the methanol extract, the fractions and standard antibiotic used were made. Holes were bored on the agar using cock bore and labeled properly. 0.05 ml of each concentration was added into the respective holes with the aid of sterile syringe and allowed to diffuse for 15-20 minutes, then incubated at 37°C (bacterial), 25°C (fungi) for 24 hours. The zone of inhibition was determined against concentration with the aid of a meter rule to the nearest millimeter. Positive control for bacteria was Ciprofloxacin 100 mg/100 ml. Ketoconazole at a dose of 100 mg/ml served as the positive control for the fungi. The extract and fractions were solubilized in DMSO. A concentration of 50 mg/ml of the plant extracts were used for the antimicrobial assay. This concentration was serially diluted seven times to yield a minimal concentration of 0.78125 mg/ml. The MIC of the fractions which showed activity, were determined using the already diluted concentrations, 10 mg/ml, 5 mg/ml, 2.5 mg/ml, 1.25 mg/ml, 0.625 mg/ml 0.3125 mg/ml and 0.15625 mg/ml. The MIC was obtained as the least concentration that had a zone of inhibition.

Statistical Analysis

Each test was carried out in triplicate. The values were expressed as mean ± standard error of mean (SEM). The Dunnett one way analysis (ANOVA) was used to determine the significant differences among all columns against control and the P value < 0.05 was considered as significant. All statistical analysis was performed using Graph Pad Prism version 8.0 software.

Results

Table 1 shows the result of phytochemical analysis of the crude methanol extract of LM. The pharmacologically important classes of secondary metabolites are contained in the mistletoe. There is a heavy presence of flavonoids, saponins and tannins in the plant compared to the phytoconstituents. Similarly, the phytochemical analysis of the peels of C. sinensis have been documented to possess alkaloid, flavonoids, terpenoids, reducing sugars, saponins, tannins and amino acid [8].

Table 1: Results from the Phytochemical Screening.

Phytochemical Constituents

Qualitative Assessment

Flavonoids

Shinoda Reduction Test

 

++

Saponins

Frothing Test

 

++

Tannins

Ferric chloride test

 

++

Alkaloids

Mayer’s test

 

+

Proteins

Million’s Test

 

+

Fats and oil

Oil Stain test

 

+

Terpenoids/Sterols

Salkwoski’s Test

 

+

Carbohydrates

Molisch test

 

+

Glycosides

Keller-killiani

 

+

Reducing sugar

Fehlings test

 

+

Resins

Copper acetate solution

 

Trace

The GCMS chemical characterization of the crude methanol extract was carried out and the results presented in Table 2. Nine compounds were identified from a spectral match with the NIST library of the equipment. There were some unidentified peaks in the GCMS chromatogram, but of the nine identified compounds, some pharmacological-active compounds with antimicrobial activities were recorded.

Table 2: GCMS Analysis Results.

No.

Compounds Retention time (RT) % Peak Area
1 Benzoic acid, 3,4,5-trimethoxy-, trimethylsilyl ester 18.061

0.64

2

1,3,5-Triazine, 2,4,6-tris[(trimethylsilyl)oxy]- 18.670 1.24
3 Benzoic acid, 3,4,5-tris(trimethylsiloxy)-, trimethylsilyl ester (gallic acid) 19.580

9.98

4

Beta.-Amyrin trimethylsilyl ether (Beta.-Amyrin) 27.060 3.52
5 Beta.-Sitosterol trimethylsilyl ether (Beta.-Sitosterol) 27.300

5.84

6

Lup-20(29)-en-3-one 27.900 15.62
7 Antra-9,10-quinone, 1-(3-hydrohy-3-phenyl-1-triazenyl)- 28.990

12.18

8

4-Dehydroxy-N-(4,5-methylenedioxy-2-nitrobenzylidene)tyramine 29.008 3.63
9 2-Thiophenecarboxylic acid, 4-methyl-5-nonadecyl-, methyl ester 29.600

2.55

The antimicrobial activities of the crude methanol extract are disclosed in Table 3. The results showed that the extract had pronounced anti-fungal activity. The results further demonstrated that the extract had less impact on gram negative bacteria in comparison to gram positive bacteria.

Table 3: Antimicrobial assay result of the crude Methanol extract.

Methanol extract

Concentration (mg/ml) /Diameter of zone of inhibition (mm) (Mean values ± SEM)
Test Organism 50 25 12.5 6.25 3.125 1.5625

0.78125

S. aureus

7.0 ± 0.0 5.3 ± 0.3 4.0+0.0 + + + +
E. coli 8.0+0.0 6.0+0.0 4.6+0.3 3.0+0.0 + +

+

B. subtilis

9.0+0.0 7.0+0.0 5.0+0.0 4.0+0.0 3.0+0.0 + +
P. aeruginosa 4.0+0.00 2.0+0.0 + + + +

+

C. albicans

11.7+0.3 10.0+0.0 8.0+0.0 6.0+0.0 4.0+0.0 2.0+0.0 +
A.niger + + + + + +

+

The fractions obtained from the crude methanol extract were evaluated for their antimicrobial activities at a lower concentration to determine their potency. These results obtained are presented in Table 4. Significantly, all the fractions had no activity against P. aeruginosa and A. niger. However, various degrees of inhibitions were recorded against the tested pathogens.

Table 4: Inhibition Zone Diameter Exhibited By The Fractions At Different Concentrations.

Fraction Conc (mg/ml)

Test Organisms
S. aureus E. coli B. subtilis P. aeruginosa C. albicans

A.niger

n-Hexane 10

5

2.5

1.25

0.625

0.3125

0.15625

6.0+0.0

4.0+0.0

3.0+0.0

+

+

+

+

5.0+0.0

3.0+0.0

+

+

+

+

+

6.0+0.0

5.0+0.0

4.0+0.0

3.0+0.0

+

+

+

+

+

+

+

+

+

+

7.0+0.0

5.0+0.0

4.0+0.0

3.0+0.0

+

+

+

+

+

+

+

+

+

+

Chloroform 10

5

2.5

1.25

0.625

0.3125

0.15625

4.0+0.0

2.9+0.1

+

+

+

+

+

+

+

+

+

+

+

+

6.0+0.0

4.0+0.0

2.0+0.0

+

+

+

+

+

+

+

+

+

+

+

6.0+0.0

4.0+0.0

3.0+0.0

2.0+0.0

+

+

+

+

+

+

+

+

+

+

Ethyl acetate 10

5

2.5

1.25

0.625

0.3125

0.15625

6.0+0.0

4.0+0.0

+

+

+

+

+

4.0+0.0

2.3+0.3

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

6.0+0.0

5.0+0.0

4.0+0.0

3.0+0.0

2.0+0.0

+

+

+

+

+

+

+

+

+

Methanol 10

5

2.5

1.25

0.625

0.3125

0.15625

4.0+0.0

2.0+0.0

+

+

+

+

+

6.0+0.0

4.0+0.0

2.0+0.0

+

+

+

+

6.0+0.0

5.0+0.0

4.0+0.0

2.0+0.0

+

+

+

+

+

+

+

+

+

+

8.0+0.0

6.0+0.0

5.0+0.0

3.0+0.0

2.0+0.0

+

+

+

+

+

+

+

+

+

Ciprofloxacin

1 mg/ml

11.3±0.3 17.3±0.6 19.7±0.3 + +
Ketoconazole

1 mg/ml

+ + + + 16.3±0.3

DMSO

+ + + + +

+

Ciprofloxacin: Positive control for bacteria; Ketoconazole: Positive control for Fungi; DMSO: Negative control; +: No inhibition.

The analysis of the MIC of the crude methanol extract and fractions are portrayed in Table 5. The key observation is that both the crude extract and the fractions exercised antifungal activities against C albicans. Except the crude methanol extract at a concentration of 25 mg/ml, all the fractions had no activity over P. aeruginosa.

Table 5: MIC of Crude methanol Extract and Fractions.

Extract/Fraction

MIC of Test Organisms

S. aureus E. coli B. subtilis P. aeruginosa

C. albicans

Methanol extract

12.5

6.25 3.125 25

1.5625

n-Hexane fraction

2.5

5 1.25 +

1.25

Chloroform fraction

5

+ 2.5 +

1.25

Ethyl acetate fraction

5

5 + +

0.625

Methanol fraction

5

2.5 1.25 +

0.625

Discussion

The citrus mistletoe is rich in flavonoids which are known to demonstrate antibacterial, anti-inflammatory and antifungal activities [9]. The presence of phenolic compounds has been attributed to antioxidant activities [10]. Flavonoids have both antifungal and antibacterial activity and anti-inflammatory properties [9]. Similarly, therapeutic benefits from alkaloids [11]and saponins [12] have been documented in literature.

The GCMS analysis of the Crude methanol extract revealed a number of peaks from which nine compounds were identified as Benzoic acid, 3,4,5-trimethoxy-, trimethylsilyl ester; 1,3,5-Triazine, 2,4,6-tris[(trimethylsilyl)oxy]-; Benzoic acid, 3,4,5-tris(trimethylsiloxy)-, trimethylsilyl ester (gallic acid); Beta-Amyrin trimethylsilyl ether (Beta-Amyrin); Beta-Sitosterol trimethylsilyl ether (Beta-Sitosterol); Lup-20(29)-en-3-one; Antra-9,10-quinone, 1-(3-hydrohy-3-phenyl-1-triazenyl)-; 4-Dehydroxy-N-(4,5-methylenedioxy-2-nitrobenzylidene)tyramine and 2-Thiophenecarboxylic acid, 4-methyl-5-nonadecyl-, methyl ester. It was discovered that the citrus mistletoe contained lupine-type triterpenes which have demonstrated significant cytotoxicities on human leukemias, melanomas and neuroblastomas. One analogue- Lup-28-al-20(29)-en-3-one, a close structural analogue of Lup-20(29)-en-3-one was the most bioactive [13].

Again the presence of gallic acid and its derivative Benzoic acid, 3,4,5-trimethoxy-, trimethylsilyl ester, strongly supports the antimicrobial activity of this mistletoe. Previous studies have documented the antimicrobial activities of gallic acid derivatives on Potato Bacterial Wilt Pathogen with 3,5-dihydroxy-4-methoxybenzoic acid shown to be the most potent one with a MIC value of 0.47 mg/ml [14].

Beta-amyrin (β-amyrin), another bioactive compound present in citrus mistletoe has been evaluated on clinical pathogens. The activity when compared with standard drugs was found to be comparable with the standard drug used [15].

β-sitosterol is the major phytosterols, found abundantly in plants is also present in citrus mistletoes. Many in vitro and in vivo studies have demonstrated various biological actions such as antimicrobial, anti – inflammatory, analgesic, immunomodulatory, anticancer, lipid lowering effect, anxiolytic & sedative effects, hepatoprotective, protective effect against NAFLD and respiratory diseases. Other effects include: wound healing effect, antioxidant and anti-diabetic activities [16]. The antimicrobial studies of novel series of 2,4-bis(hydrazino)-6-substituted-1,3,5-triazine and their Schiff base derivatives was carried using S. aureus, and E. coli among the pathogens evaluated. The 1,3,5-triazine were found to demonstrate significant activity on bacteria in microgram/ml range, but no antifungal activity was observed. It may be suggested that the presence of 1,3,5-triazine in the mistletoe contributed to the observed activity against the gram positive bacteria [17].

Conclusion

The results of the analyses shown earlier have demonstrated that the leaves of L. micranthus Linn parasitic on Citrus sinensis possess very potent antifungal activities against C. albicans and thus could be used as a therapeutic preparation in treatment of fungal Infections. Also, from the results the fractions displayed varying degree of antimicrobial activity against S. aureus, E. coli and B. subtilis. While P. aeruginosa and A. niger could not be inhibited by the fractions at the test concentrations. This suggests that the extracts had more activity against gram positive bacteria than against gram negative bacteria. The antimicrobial activity of the citrus mistletoe merits further research as the plant has potentials for development into antimicrobial agent that can be used in treating infections. Again, given that the plant contains some reported antimicrobial compounds, this might be exploited in the design and development fungicidal and bactericidal drugs.

Conflict of Interest

No potential conflict of interest was reported by the authors.

References

  1. Xu Q, Chen LL, Ruan X, Chen D, Zhu A, et al. (2013) “The draft genome of sweet orange (Citrus sinensis)”. Nature Genetics 45: 59-66. [crossref]
  2. “Citrus sinensis” (2017) Germplasm Resources Information Network (GRIN). Agricultural Research Service (ARS), United States Department of Agriculture (USDA).
  3. Production, Crops, World Regions (2018) United Nations, Food and Agricultural Organization, FAO Statistics.
  4. Moghadamtousi SZ, Hajrezaei M, Abdul Kadir H, Zandi K (2013) Loranthus micranthus Linn.: Biological Activities and Phytochemistry. Evidence-Based Complementary and Alternative Medicine 2013: 273712. [crossref]
  5. Osadebe PO, Johnson-Ajinwo OR (2010) A Review of the Bio-Activity Relationship of Mistletoes and the Leaves of their Host Trees. Nigerian Journal of Pharmaceutical Research 8: 145-150.
  6. Evans WC, Evans D, Trease GE (2002) Trease and Evans’ Pharmacognosy. 15th Edition, Publisher: WB Saunders, Edinburgh ; New York.
  7. Seeley HW, Van Denmark PJ (1975) “Microbes in action” in A Laboratory manual of Microbiology. 2nd ed. Bombay: D B. Taraporewala Sons and Co 55-80.
  8. Baba J, Mohammed SB, Ya’aba Y, Umaru FI (2018) Antibacterial Activity of Sweet Orange (Citrus sinensis) on some Clinical Bacteria Species Isolated from Wounds. J Family Med Community Health 5: 1154
  9. Iwu MW, Duncan AR, Okunji CO (1999) New antimicrobials of plant origin. In: Janick J (Ed.), perpectives on New uses. ASHS press Alexandria. VA, 457-462.
  10. Gomez-Alonso S, Fregapane G, Salvador MD, Gordon MH (2003) Changes in phenolic composition and antioxidant activity of virgin olive oil during frying. Agric. Food Chem 51: 667-672. [crossref]
  11. Njoku PC, Akumefula MI (2007) Phytochemical and Nutrient Evaluation of Spondias mombin Leaves. Parkistan Journal of Nutrition 6: 613-615.
  12. Rabe T, van Staden J (2000) Isolation of an antibacterial sesquiterpenoid from Warburgia salutaris. Ethnopharmacol 73: 171-174. [crossref]
  13. Keishi H, Kazuyuki H, Hironobu O, Takahashi S (2003) Anti-leukemia activities of Lup-28-al-20(29)-en-3-one, a lupane triterpene. Toxicology Letters 143: 1-7. [crossref]
  14. Mohamed A, Farag Dalia A, Al-Mahdy R, El Dine S, Fahmy S, et al. (2015) Structure Activity Relationships of Antimicrobial Gallic Acid Derivatives from Pomegranate and Acacia Fruit Extracts against Potato Bacterial Wilt Pathogen. Chemistry & Biodiversity 12: 955-962. [crossref]
  15. Ogwuche CE, Amupitan JO, Ndukwe IG, Ayo RG (2014) Isolation and Biological Activity of the Triterpene Β-Amyrin from the Aerial Plant Parts of Maesobotrya Barteri (Baill). Med chem 4: 729-733.
  16. Babu S, Jayaraman S (2020) An update on β-sitosterol: A potential herbal nutraceutical for diabetic management. Biomedicine & Pharmacotherapy 131: 110702. [crossref]
  17. Al-Rasheed HH, Sholkamy EN, Al Alshaikh M, Mohammed RH, Siddiqui MRH, et al. (2018) Synthesis, Characterization, and Antimicrobial Studies of Novel Series of 2,4-Bis(hydrazino)-6-substituted-1,3,5-triazine and Their Schiff Base Derivatives. Hindawi Journal of Chemistry 2018: 8507567.